CA2318100A1 - Chemokine receptor antagonists and methods of use therefor - Google Patents
Chemokine receptor antagonists and methods of use therefor Download PDFInfo
- Publication number
- CA2318100A1 CA2318100A1 CA002318100A CA2318100A CA2318100A1 CA 2318100 A1 CA2318100 A1 CA 2318100A1 CA 002318100 A CA002318100 A CA 002318100A CA 2318100 A CA2318100 A CA 2318100A CA 2318100 A1 CA2318100 A1 CA 2318100A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- substituted
- ring
- aromatic
- aliphatic group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 55
- 229940122444 Chemokine receptor antagonist Drugs 0.000 title description 2
- 239000002559 chemokine receptor antagonist Substances 0.000 title description 2
- 125000003118 aryl group Chemical group 0.000 claims abstract description 101
- 150000001875 compounds Chemical class 0.000 claims abstract description 98
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 78
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims abstract description 53
- 125000001743 benzylic group Chemical group 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 230000004913 activation Effects 0.000 claims abstract description 24
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 23
- 230000007115 recruitment Effects 0.000 claims abstract description 17
- 230000001594 aberrant effect Effects 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 12
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
- 208000030507 AIDS Diseases 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- 125000003435 aroyl group Chemical group 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 125000001589 carboacyl group Chemical group 0.000 claims description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 125000005518 carboxamido group Chemical group 0.000 claims description 6
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010037868 Rash maculo-papular Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 208000037902 enteropathy Diseases 0.000 claims description 2
- 201000005884 exanthem Diseases 0.000 claims description 2
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010037844 rash Diseases 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims 6
- 208000026935 allergic disease Diseases 0.000 claims 1
- -1 MIP-ia Proteins 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 238000002360 preparation method Methods 0.000 description 31
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 238000005160 1H NMR spectroscopy Methods 0.000 description 22
- 102000019034 Chemokines Human genes 0.000 description 21
- 108010012236 Chemokines Proteins 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 108010055166 Chemokine CCL5 Proteins 0.000 description 17
- 239000005557 antagonist Substances 0.000 description 17
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 16
- 101150041968 CDC13 gene Proteins 0.000 description 15
- 102000009410 Chemokine receptor Human genes 0.000 description 15
- 108050000299 Chemokine receptor Proteins 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 238000009739 binding Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- LCVQTDUGLFVCGP-UHFFFAOYSA-N 11h-dibenzo[1,2-a:1',2'-e][7]annulene-11-carbonitrile Chemical compound C1=CC2=CC=CC=C2C(C#N)C2=CC=CC=C21 LCVQTDUGLFVCGP-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000027455 binding Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 7
- 239000012280 lithium aluminium hydride Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 102000001902 CC Chemokines Human genes 0.000 description 6
- 108010040471 CC Chemokines Proteins 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- LZAYOZUFUAMFLD-UHFFFAOYSA-N 4-(4-chlorophenyl)-4-hydroxypiperidine Chemical compound C=1C=C(Cl)C=CC=1C1(O)CCNCC1 LZAYOZUFUAMFLD-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000002975 chemoattractant Substances 0.000 description 4
- 230000035605 chemotaxis Effects 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 3
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FTGVWSKYBMZSOE-UHFFFAOYSA-N 6,11-dihydro-5h-dibenzo[1,2-a:1',2'-e][7]annulene-11-carbonitrile Chemical compound C1CC2=CC=CC=C2C(C#N)C2=CC=CC=C21 FTGVWSKYBMZSOE-UHFFFAOYSA-N 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 2
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 2
- 108050006947 CXC Chemokine Proteins 0.000 description 2
- 102000019388 CXC chemokine Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- 102100036154 Platelet basic protein Human genes 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 108010086192 chymostatin Proteins 0.000 description 2
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N cycloheptane Chemical group C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229910052760 oxygen Chemical group 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 0 ****N1CCNCC1 Chemical compound ****N1CCNCC1 0.000 description 1
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical class O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- HLJAUIIGTPYTIX-UHFFFAOYSA-N 11-[3-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]propyl]-5,6-dihydrodibenzo[1,2-a:1',2'-e][7]annulene-11-carbonitrile Chemical compound C1CN(CCCC2(C#N)C3=CC=CC=C3CCC3=CC=CC=C32)CCC1(O)C1=CC=C(Cl)C=C1 HLJAUIIGTPYTIX-UHFFFAOYSA-N 0.000 description 1
- YKFWLTHKZUBSHE-UHFFFAOYSA-N 11-[3-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]propyl]-6h-benzo[c][1]benzoxepine-11-carbonitrile Chemical compound C1CN(CCCC2(C#N)C3=CC=CC=C3OCC3=CC=CC=C32)CCC1(O)C1=CC=C(Cl)C=C1 YKFWLTHKZUBSHE-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical group CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- DLYXJTPXEXTGSO-UHFFFAOYSA-N 2-bromo-6,11-dihydrobenzo[c][1]benzothiepine-11-carbonitrile Chemical compound S1CC2=CC=CC=C2C(C#N)C2=CC(Br)=CC=C21 DLYXJTPXEXTGSO-UHFFFAOYSA-N 0.000 description 1
- YBGYPMUSDHAMQA-UHFFFAOYSA-N 2-bromo-6,11-dihydrobenzo[c][1]benzoxepine-11-carbonitrile Chemical compound O1CC2=CC=CC=C2C(C#N)C2=CC(Br)=CC=C21 YBGYPMUSDHAMQA-UHFFFAOYSA-N 0.000 description 1
- MTAAFMQHXPYUEL-UHFFFAOYSA-N 2-fluoro-6,11-dihydrobenzo[c][1]benzoxepine-11-carbonitrile Chemical compound O1CC2=CC=CC=C2C(C#N)C2=CC(F)=CC=C21 MTAAFMQHXPYUEL-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- PUIQEDWBNJPKRN-UHFFFAOYSA-N 2-methyl-6,11-dihydrobenzo[c][1]benzoxepine-11-carbonitrile Chemical compound O1CC2=CC=CC=C2C(C#N)C2=CC(C)=CC=C21 PUIQEDWBNJPKRN-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- UYWWLYCGNNCLKE-UHFFFAOYSA-N 2-pyridin-4-yl-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1C1=CC=NC=C1 UYWWLYCGNNCLKE-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical class C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
- GAWFMHCEEJDUEF-UHFFFAOYSA-N 3,4-dichloro-6,11-dihydrobenzo[c][1]benzoxepine-11-carbonitrile Chemical compound C1OC2=C(Cl)C(Cl)=CC=C2C(C#N)C2=CC=CC=C21 GAWFMHCEEJDUEF-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QNLXJYQUWCNYBH-UHFFFAOYSA-N 4-(4-bromophenyl)piperidin-4-ol Chemical compound C=1C=C(Br)C=CC=1C1(O)CCNCC1 QNLXJYQUWCNYBH-UHFFFAOYSA-N 0.000 description 1
- QXWRXWPNHLIZBV-UHFFFAOYSA-N 4-(4-fluorophenyl)piperidin-4-ol Chemical compound C=1C=C(F)C=CC=1C1(O)CCNCC1 QXWRXWPNHLIZBV-UHFFFAOYSA-N 0.000 description 1
- KQKFQBTWXOGINC-UHFFFAOYSA-N 4-phenylpiperidin-4-ol Chemical compound C=1C=CC=CC=1C1(O)CCNCC1 KQKFQBTWXOGINC-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QZQJDRXKYAKUII-UHFFFAOYSA-N 6,11-dihydrobenzo[c][1]benzoxepine-11-carbonitrile Chemical compound C1OC2=CC=CC=C2C(C#N)C2=CC=CC=C21 QZQJDRXKYAKUII-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- QLDZLSZSVUNEOG-UHFFFAOYSA-N C1=C2C(C#N)C3=CC=CC=C3COC2=CC2=C1OCO2 Chemical compound C1=C2C(C#N)C3=CC=CC=C3COC2=CC2=C1OCO2 QLDZLSZSVUNEOG-UHFFFAOYSA-N 0.000 description 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 101100219997 Mus musculus Ccr1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- VOQCAGSVXAQOKW-UHFFFAOYSA-N bis(2-methylpropyl)alumane dichloromethane Chemical compound ClCCl.[H][Al](CC(C)C)CC(C)C VOQCAGSVXAQOKW-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- ANUZKYYBDVLEEI-UHFFFAOYSA-N butane;hexane;lithium Chemical compound [Li]CCCC.CCCCCC ANUZKYYBDVLEEI-UHFFFAOYSA-N 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical group C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Chemical group 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- KCPSKGICNNZWJA-UHFFFAOYSA-N ethyl 3-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]propanoate Chemical compound C1CN(CCC(=O)OCC)CCC1(O)C1=CC=C(Cl)C=C1 KCPSKGICNNZWJA-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- OKNBXQKCQLCCMA-UHFFFAOYSA-N phenyl n-[5-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-2-(6,11-dihydrobenzo[c][1]benzothiepin-11-yl)pentyl]carbamate Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(C1C2=CC=CC=C2SCC2=CC=CC=C21)CNC(=O)OC1=CC=CC=C1 OKNBXQKCQLCCMA-UHFFFAOYSA-N 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- LFAGQMCIGQNPJG-UHFFFAOYSA-N silver cyanide Chemical compound [Ag+].N#[C-] LFAGQMCIGQNPJG-UHFFFAOYSA-N 0.000 description 1
- 229940098221 silver cyanide Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to the subject a therapeutically effective amount of a compound represented by structural formula (I), and physiologically acceptable salts thereof. Z is a cycloalkyl or non-aromatic heterocyclic ring group fused to one or more carbocyclic aromatic rings and/or heteroaromatic rings, wherein each ring in Z is independently substituted or unsubstituted; Y is a covalent bond, -O- or -CO-; n is an integer from one to about five; X is a covalent bond or -CO-; and M is NR2, CR1R2; R1 is -H, -OH, an aliphatic group, -O- (aliphatic group), -SH or -S- (aliphatic group); R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group.
Description
WO 99/3761? PCT/US99/01265 CHEMOKINE RECEPTOR ANTAGONISTS
AND METHODS OF USE THEREFOR
RELATED APPLICATIONS
This application is a continuation-in-part of U.S.
Serial No. 09/010,321, filed January 21, 1998, which is a continuation-in-part of U.S. Serial No. 08/891,518, filed July 11, 1997, which claims priority to U.S. Provisional Application Serial No. 60/021,716, filed July 12, 1996, the entire teachings of which are hereby incorporated by reference.
BACKGROUND OF THE INVENTION
Chemoattractant cytokines or chemokines are a family of proinflammatory mediators that promote recruitment and activation of multiple lineages of leukocytes and lymphocytes. They can be released by many kinds of tissue cells after activation. Continuous release of chemokines at sites of inflammation mediates the ongoing migration of effector cells in chronic inflammation. The chemokines characterized to date are related in primary structure.
They share four conserved cysteines, which form disulfide bonds. Based upon this conserved cysteine motif, the family is divided into two main branches, designated as the C-X-C
chemokines (a-chemokines), and the C-C chemokines (~i-chemokines), in which the first two conserved cysteines are separated by an intervening residue, or adjacent respectively (Baggiolini, M. and Dahinden, C. A., Imnrurtology Today, 15:127-133 (1994) ) .
WO 99/37617 PC'T/US99/01265 The C-X-C chemokines include a number o~ potent chemoattractants and activators of neutrophils, such as interleukin 8 (IL-8), PF4 and neutrophil-activating peptide-2 (NAP-2). The C-C chemokines include nANTES
(Regulated on 8ctivation, Normal T Expressed and Secreted), the macrophage inflammatory proteins la and la (MIP-la and MIP-1(3), and human monocyte chemotatic proteins 1-3 (MCP-1, MCP-2, MCP-3), which have been characterized as chemoattractants and activators of monocytes or lymphocytes but do not appear to be chemoattractants for neutrophils.
Chemokines, such as RANTES and MIP-la, have been implicated in a wide range of human acute and chronic inflammatory diseases including respiratory diseases, such as asthma and allergic disorders.
The chemokine receptors are members of a superfamily of G protein-coupled receptors (GPCR) which share structural features that reflect a common mechanism of action of signal transduction (Gerard, C. and Gerard, N.P., Annu Rev. Immunol., 12:775-808 (1994); Gerard, C. and Gerard, N. P., Curr. Opin. Immunol., 6:140-145 (1994)).
Conserved features include seven hydrophobic domains spanning the plasma membrane, which are connected by hydrophilic extracellular and intracellular loops. The majority of the primary sequence homology occurs in the hydrophobic transmembrane regions with the hydrophilic regions being more diverse. The first receptor for the C-C
chemokines that was cloned and expressed binds the chemokines MIP-la and RANTES. Accordingly, this MIP-la/RANTES receptor was designated C-C chemokine receptor 1 (also referred to as CCR-1; Neote, K., et al., Cell, 72:415-425 (1993); Horuk, R. et al., WO 94/11504, May 26, 1994; Gao, J.-I. et al., J. Exp. Med., 177:1421-1427 (1993)). Three new receptors have been characterized which bind and/or signal i:i response to RP.IvTES : CCR3 med~.ates binding and signaling of chemokines including eotaxin, RANTES, and MCP-3 (Ponath et al., J. Exp. Med., 183:2437 (1996)), CCR4 binds chemokines including RANTES, MIP-ia, and MCP-1 (Power, et al., J. Biol. Chem., 276:19495 (1995)), and CCR5 binds chemokines including MIP-la, RANTES, and MIP-1(3 (Samson, et al., Biochem. 35: 3362-3367 (1996)). RANTES is a chemotactic chemokine for a variety of cell types, including monocytes, eosinophils, and a subset of T-cells. The responses of these different cells may not all be mediated by the same receptor, and it is possible that the receptors CCR1, CCR4 and CCR5 will show some selectivity in receptor distribution and function between leukocyte types, as has already been shown for CCR3 (Ponath et al.). In particular, the ability of RANTES to induce the directed migration of monocytes and a memory population of circulating T-cells (Schall, T. et al., Nature, 347:669-71 (1990)) suggests this chemokine and its receptors) may play a critical role in chronic inflammatory diseases, since these diseases are characterized by destructive infiltrates of T cells and monocytes.
Many existing drugs have been developed as antagonists of the receptors for biogenic amines, for example, as antagonists of the dopamine and histamine receptors. No successful antagonists have yet been developed to the receptors for the larger proteins such as chemokines and CSa. Small molecule antagonists of the interaction between C-C chemokine receptors and their ligands, including RANTES
and MIP-la, would provide compounds useful for inhibiting harmful inflammatory processes "triggered" by receptor ligand interaction, as well as valuable tools for the investigation of receptor-ligand inter~~tions.
SUMMARY OF THE INVENTION
rt has now been found that a number of small organic molecules are antagonists of chemokine receptor function and can inhibit leukocyte activation and/or recruitment.
An antagonist of chemokine receptor function is a molecule which can inhibit the binding of one or more chemokines, including C-C chemokines such as RANTES and/or MIP-la, to one or more chemokine receptors on leukocytes and/or other cell types. As a consequence, processes and cellular responses mediated by chemokine receptors can be inhibited with these small organic molecules. Based on this discovery, a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation is disclosed. The method comprises administering to the subject a therapeutically effective amount of a compound cr small organic molecule which is an antagonist of chemokine receptor function. Compounds or small organic molecules which have been identified as antagonists of chemokine receptor function are discussed in detail hereinbelow, and can be used for the manufacture of a medicament for treating or for preventing a disease associated with aberrant leukocyte recruitment and/or activation. The invention also relates to the disclosed compounds and small organic molecules for use in treating or preventing a disease associated with aberrant leukocyte recruitment and/or activation. The invention also includes S
pharmaceutical compositions comprising one or_ more of the compounds or small organic molecules which have been identified herein as antagonists of chemokine function and a suitable pharmaceutical carrier. The invention further 5 relates to novel compounds which can be~used to treat an individual with a disease associated with aberrant leukocyte recruitment and/or activation.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is a schematic showing the preparation of the 10 compounds represented by Structural Formulas (I).and (II).
Figure 2 is a schematic showing the preparation of the compounds represented by Structural Formula ((I) and II), wherein Z is representea b1 St ~~crural Formulas (IV) and wherein Ring A in Z is substituted with 15 - (CH2) t-COOH, - (CHZ) t-COOR2° or - (CH2) t-C (O) -NRZIRzz Figure 3 is a schematic showing the preparation of the compounds represented by Structural Formula (I) and (II), wherein Z is represented by Structural Formulas (VIII) and (XI II ) - (XVI ) and wherein V is Wa .
20 Figure 4A - 4F show the structures of a number of exemplary compounds of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to small molecule compounds which are antagonists of chemokine receptor 25 function. Accordingly, processes or cellular responses mediated by the binding of a chemokine to a receptor can be inhibited (reduced or prevented, in whole or in part), including leukocyte migration, integrin activation, transient increases in the concentration of intracellular free calcium [Ca'-] i, and/or granule rel ease of proinflammatory mediators.
The invention further relates to a method of treatment, including prophylactic and therapeutic treatments, of a disease associated with aberrant leukocyte recruitment and/or activation or mediated by chemokines or chemokine receptor function, including chronic irflam«;atory disorders characterized by the presence of RANTES, MI.-la, MCP-2, MCP-3 and/or MCP-4 responsive T cells, monocytes and/or eosinophils; including but not limited to diseases such as arthritis (e. g., rheumatoid arthritis), atherosclerosis, arteriosclerosis, ischemia/reperfusion injury, diabetes mellitus (e. g., type 1 diabetes mellitus), psoriasis, multiple sclerosis, inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, rejection of transplanted organs and tissues (i.e., acute allograft rejection, chronic allograft rejection), graft versus host disease, as well as allergies and asthma. Other diseases associated with aberrant leukocyte recruitment and/or activation which can be treated (including prophylactic treatments) with the methods disclosed herein are inflammatory diseases associated with Human Immunodeficiency Virus (HIV) infection, e.g., AIDS
associated encephalitis, AIDS related maculopapular skin eruption, AIDS related interstitial pneumonia, AIDS related enteropathy, AIDS related periportal hepatic inflammation and AIDS related glomerulo nephritis. The method comprises administering to the subject in need of treatment an effective amount of a compound (i.e., one or more compounds) which inhibits chemokine receptor function, inhibits the binding of a chemokine to leukocytes and/or other cell types, and/or which inhibits leukocyte migration to, and/or activation at, sites of inflammation. According to the method, chemc~cine-mediated chemotaxis and/or activation of pro-~;lammatory cells bearing receptors for chemokines can be inhibited. As used herein, ~~pro-inflammatory cells" includes but is not limited to leukocytes, since chemokine receptors may be expressed on other cell types, s;~ch as neurons and epithelial cells.
In one embodiment of the present invention, the antagonist of chemokine receptor function is represented by Structural Formula (I):
Z Y C X-N
~.~n M
(I) Z is a cycloalkyl or non-aromatic heterocyclic ring fused to one or more carbocyclic aromatic rings and/or heteroaromatic rings.
Y is a covalent bond, -O- or -CO-.
n is an integer from one to about five. n is preferably one, two, or three.
X is a covalent bond or -CO-.
M is >NR2 or >CR1R2. Preferably, M is >C (OH) Rz.
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group). Preferably, R: is -H
or -OH.
Rz is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a a WO 99/37617 PCT/US99/01265 benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group. Preferably, RZ is an aromatic or a substituted aromatic group.
In a preferred embodiment, -X- and -Y- in Structural Formula (I) are each a covalent bond and the antagonist of chemokine receptor function is a compound represented by Structural Formula (II):
Cu~~
Z C ~tr--N M
(II) Z, n and M are as described above for Structural Formula (I) .
In another preferred embodiment, -X- is a covalent bond, -Y- is -CO- and the antagonist of chemokine receptor function is a compound represented by Structural Formula (III) O
Z/ \ (C
~~r-- M
(III) Preferably, Z is a tricyclic ring system comprising two carbocyclic aromatic groups fused to a seven or eight membered cycloalkyl group or to a non-aromatic heterocyclic ring. In one example, Z is represented by Structural Formula (IV) !~ I C I
(IV) The phenyl rings in Structural Formula (IV), labeled with an "A" and "B", are referred'to herein as "Ring A" and "Ring B", respectively. The central ring, labeled with a "C", is referred to as "Ring C" and can be, for example a six, seven or eight membered non-aromatic carbocyclic ring (e. g., a cycloheptane or cyclooctane ring) or a non-aromatic heterocyclic ring. When Ring C is a non-aromatic heterocyclic ring, it can contain one or two heteroatoms such as nitrogen, sulfur or oxygen. When Z is represented by Structural Formula (IV), the tricyclic ring system is connected to Y in Structural Formula (I) by a single covalent bond between Y and a ring atom in Ring C.
Ring A and/or Ring B can be unsubstituted.
Alternatively, Ring A and/or Ring B can have one or more substituents. Suitable substituents are as described hereinbelow for substituted aromatic groups. In one example, Ring A or Ring B is substituted with -(CHZ)t-COON, - (CHZ) C-COOR'° or - (CHZ) C-C (O) -NRZ1R22.
t is an integer from zero to about 3.
RZ°, Rz= or RZ2 are independently -H, an aliphatic group a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or -NHC(O)-O-(non-aromatic 5 heterocyclic group). In addition, R'1 and R", taken together with the nitrogen atom to which they are bonded, can form a non-aromatic heterocyclic ring.
Ring C optionally contains one or more additional substituents. When Ring C is a non-aromatic carbocyclic 10 ring, suitable substituents are as described hereinbelow for substituted aliphatic groups. When Ring C contains one or more heteroatoms, suitable substituents are as described below for non-aromatic heterocyclic rings. Preferably, Ring C is unsubstituted or substituted with an electron withdrawing group. Suitable electron withdrawing groups include -CN, alkylsulfonyl, carboxamido, carboxylic alkyl esters, -NO2 and halogens (e. g., -Br and -C1).
Alternatively, Ring C is substituted with a group selected from -CH2-NR11R1', -CHZ-OR11, -CH2-NH-CO-NR11R1~, -CH2-O-CO-NR'1R1'.
Ril and R'2 are independently -H, an aliphatic group a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), or NHC (O) -O- (aromatic group) . In addition, R'1 and Rlz, taken together with the nitrogen atom to which they are bonded, can form a non-aromatic heterocyclic ring.
Examples of suitable tricyclic rings systems represented by Structural Formula (IV) are provided by Structural Formula (V)-(VIII), shown below:
\ x, \ \ x, \
A I B I A I B
/ / ~ /
w ,~ W f (V) (VI) Xi ~ ~ X~
I A I B I A I B
/ / / /
f Wa (VII) We f (VIII}
Xl is a chemical bond, -S-, -CHZ- or -CHZS- .
Preferably, X1 is -S- in Structural Formulas (V) and (VII).
Preferably, X1 is -CHZS- in Structural Formulas (VI) and (VIII) .
W is -H or an electron withdrawing group, as described above for Structural Formula (IV). A preferred electron withdrawing group is -CN.
Wa is a group selected from -CH2-NR1'R12, -CHZ-OR11, -CI-:~-NH-CO-NR=iR=' or -CHZ-O-CO-NRllR~z. R1'- and R=' are as defined in Structural Formula (IV).
Ring A and Ring B in Structural Formulas (V)-(VIII) are as described above in Structural Formula (IV).
Other examples of suitable tricyclic ring systems represented by Structural Formula (IV) are shown below in Structural Formulas (IX)-(XII), (XIIa), (XIIb) an (XIIc):
W W iA o~ iB
(IX) (X) Rc~ p A NC I B
A C B
/ / / /
(XI) (XII) \ ~°2 \
A C B I A C I B
/ / / /
(XIIa) (XIIb) A C I B
/ /
(XIIc) Rings A-C in Structural Formulas (IX)-(XII), (XIIa), (XIIb) and (XIIc) are as described for Structural Formula (IV) .
R_ is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group; a benzyiic group or a substituted benzylic group.
Preferably, R~ is a substituted C1-C20 aliphatic group, a C10-C20 aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group or a substituted benzylic groin. T~ one example, R, is - (CHI) S-COON, - (CH2) ~-COOR" or - (CH. 1 =-C (O) -NR31R3z .
s is an integer from zero to about 3.
R'°, R'1 and R'2 are independently -H, an aliphatic group a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or -NHC(O)-O-(non-aromatic heterocyclic group) . In addition, R31 and R32, taken together with the nitrogen atom to which they are bonded, can form a non-aromatic heterocyclic ring.
Preferred examples of tricyclic ring systems represented by Structural Formulas (IX)-(XII),(XIIa), (XIIb) and (XIIc) are shown below in Structural Formulas (XIT_I) - (XVI) , (XVIa) , (XVIb) and (XVIc) WO PC1'/US99/OiZ6S
\ \ \ \
O
I I B I A I B
.A
/ / / /
V ~~ V
(XIII) (XIV) O
IA IB iA I B
/ / / /
V \~ V ~' (XV) (XVI) \ so \ \so2 ,\
A I B I A I B
/ / / /
V ~ (XVIb) v \~ (XVIa) A B
/ /
v ~ (XVIc) 1$
V is W or Wa, which are as described above for Structural Formula (V) - (VIII) .
In another preferred embodiment, Z is a tricyclic ring system comprising one or more heteroaromatic groups fused to a seven or eight membered cycloalkyl group or to a non-aromatic heterocyclic ring. Examples are represented by Structural Formulas (XVII)-(XXI), (XXIa), (XXIb) and (XXIc) AI I B
w~~,~' we f b (XVII) . (XVIII) AI I B
wti ~~ (XIX) ~yb ,/
J
( Rcv i~
B
We ~~' (XXIa) Wb ~ (XXIb) RcN
B
W ti ~ (XXIC) Ring A in Structural Formulas (XVII)-(XXI), (XXIa), (XXIb) and (XXIc) is a substituted or unsubstituted aromatic group.
Ring B in Structural Formulas (XVII)-(XXI), (XXIa), (XXIb) and (XXIc) is a substituted or unsubstituted heteroaryl group.
W,. is -H, -CN, -CHz-NR'1R1°, -CH2-OR'1, -CH2-NH-CO-NRllRlz -CHZ-O-CO-NR'1R1=. Rl' and Rw are as defined above for Structural Formula (IV).
In yet another preferred embodiment, the antagonist of chemokine function is a compound represented by Structural Formula (XXII and (XXIII):
X~ \ \ X~
A I B A I B
/ / / /
(CH z)\ W (CH z)\
M M
(XXII) (XXIII) In Structural Formulas (XXII) and (XXIII), X1 is as defined above for Structural Formulas (V) and (VI); n is an integer from two to five; W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl.
In Structural Formulas (XXII) and (XXIII), Ring A is substituted with Re and R9, wherein Re and R9 are independently -H, a halogen, alkoxy or alkyl, or, taken together with ring A, form a naphthyl group. M is >N(alkanoyl), >N(aroyl), >N(aralkoyl), >N(alkyl), >N(aralkyl), >N(cycloalkyl), >C(OH)(aryl) or >CH(heteroaryl).
The present invention also includes novel compounds represented by Structural Formulas (II) and (III).
In one embodiment, the novel compounds are represented by Structural Formulas (II) and (III) wherein Z is a group in which one or more heteroaromatic rings are fused to a cycloalkyl ring or a non-aromatic heterocyclic ring. Each ring in Z is independently substituted or unsubstituted.
Examples of suitable Z groups are represented by Structural Formulas (XVII ) - (XXI ) , (XXIa) , (XXIb) and (XXIc ) . Ring A, Ring B, M, Wb, R:, Rz, R~ and n are as described in StrucLUral Formulas (XVII) through (XXIc).
In another embodiment, the novel compounds are represented by Structural Formulas (II) and (III) have a Z
group represented by Structural Formulas (V) and (VI). At least one of Ring A or Ring B is substituted. M, W, R:, Rz and n are as described in Structural Formulas (v) and (VI).
In another embodiment, the novel ccmpounds represented by Structural Formulas (II) and (III) have a Z group represented by Structural Formulas (VII) and (VIII). Ring A, Ring B, M, Wa, R1, R2 and n are as described in Structural Formulas (VII) and (VIII).
In another embodiment, the novel compounds represented by Structural Formulas (II) and (III) have a Z group represented by Structural Formulas (XIII)-(XVI), (XVIa), (XVIb) and (XVIc) . Ring A, Ring B, M, R1, R2, R~ and n are as described in Structural Formulas (XIII) through (XVIc).
V is -CN, -CH2-NRl'Rl~, -CH2-OR'1, -CH2-NH-CO-NR'1R", -CH--O-CO-NR==R='. R-- and Ri' are as def fined above for Structural Formula (IV).
In another embodiment, the novel compounds represented by Structural Formulas (II) and (III) have a Z group represented by Structural Formula (XVI). Ring A, Ring B, M, R., R~, and n are as described in Structural Formula (XVI). V is -H and R~ is a C10-C20 aliphatic group, a substituted C10-C20 aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group or a substituted benzylic group. In one example, R_ is - (CHz) $-COOH, - (CHz) S-COOR3° or - (CHz) S-C (O) -NR'iR'~, wherein s, R'°, R'1 and R'Z are as desribed above. Preferably, R~ is an aromatic group, a substituted aromatic group, a benzylic group or a substituted benzylic group.
In yet another embodiment, the novel compounds represented by Structural Formula (II) and (III) have a Z
group represented by Structural Formulas (XXII) and (XXIII). Ring A, Ring B, M, W, and r. are as described in Structural Formulas (XXII) through (XXIII). Re and R9 are independently a halogen, alkoxy or alkyl, or, taken together with ring A, form a naphthyl group.
Also included in the present invention are physiologically acceptable salts of the compounds represented by Structural Formulas (I) through (XXIII).
Salts of compounds containing an amine or other basic group can be obtained, for example, by reacting with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like. Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like. Salts of compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base, for example, a hydroxide base. Salts of acidic functional groups contain a countercation such as sodium, potassium and the like.
As used herein, aliphatic groups include straight chained, branched or cyclic C~-Ce hydrocarbons which are completely saturated or which contain one or more units of unsaturation.
WO 99/37617 2o PCT/US99/OtZ65 An "alkyl group" is a saturated aliphatic group, as defined above. The term "alkoxy" refers to an alkyl ether chain with ar. alkyl group. "Alkanoyl" refers to alkyl substituted carbonyl; "aralkanoyl" refers to phenyl-alkyl-CO- and "aroyl" refers to arylcarbonyl including benzoyl, naphthoyl and the like. The term "halogen" means fluoro, chloro, bromo and iodo. The term "aryl", as opposed to the term "aromatic group", means phenyl. The term "substituted phenyl" means aryl substituted by alkyl, halogen, alkoxy, vitro, amino, acetamido, cyano and trifluoromethyl and naphthyl.
"Aralkyl" means -(CHZ)X-phenyl, wherein x is an integer from one to four including benzyl. It is noted that the terms "aromatic group", "carbocylic aromatic group" and "heterocyclic aromatic group" are defined below and have different meanings from the term "aryl".
Aromatic groups include carbocyclic aromatic groups such as phenyl, 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthacyl, and heterocyclic aromatic groups such as N-imidazolyl, 2-imidazole, 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidy, 4-pyrimidyl, 2-pyranyl, 3-pyranyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-pyrazinyl, 2-thiazole, 4-thiazole, 5-thiazole, 2-oxazolyl, 4-oxazolyl and 5-oxazolyl.
Aromatic groups also include fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings. Examples include 2-benzothienyl, 3-benzothienyl, 2-benzofuranyl, 3-benzofuranyl, 2-indolyl, 3-indolyl, 2-quinolinyl, 3-quinolinyl, 2-benzothiazole, 2-benzooxazole, 2-benzimidazole, 2-quinolinyl, 3-quinolinyl, 1-isoquinolinyl, 3-quinolinyl, 1-isoindolyl, 3-isoindolyl, and acridintyl. Also included within the scope of the term "aromatic group", as it is used herein, is a group in which one or more carbocyclic aromatic rings and/or heteroaromatic rings are fused to a cycloalkyl or non-aromatic heterocyclic ring. Examples include decalin, phthalimido, benzodiazepines, benzooxazepines, benzooxazines, phenothiazines, and groups represented by the following structural formulas:
5 \ \ \
o / 5 I / , .
or WO 99!37617 PCT/US99/01165 Non-aromatic heterocyclic rings are non-aromatic carbocyclic rings which include one or more heteroatoms such as nitrogen, oxygen or sulfur in the ring. The rinc can be five, six, seven or eight-membered. Examples include 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahyrothiophenyl, 3-tetrahyrothiophenyl, 2-morpholirc, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyi, 4-piperidinyl and 4-thiazolidinyl.
"Heterocyclic ring", as opposed to "heteroaryl group"
and "non-aromatic heterocylic ring", is defined as imidazole, benzimidazole, pyridine, pyrimidine, thiazole, benzothiazole, thienyl, benzothienyl. It is noted further the terms "heterocyclic aromatic group" and "non-aromatic heterocyclic ring" are defined above and have different meanings from the term "heterocyclic ring".
Suitable substituents on an alkyl, aliphatic, aromatic, non-aromatic heterocyclic ring or benzyl group include, for example, -OH, halogen (-Br, -C1, -I and -F) -O(aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group), -CN, -N~~, -COOH, -NHZ, -NH(aliphatic group, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group), -N(aliphatic group, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group ), -COO(aliphatic group, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group), -CONHz, -CONH(aliphatic, substituted aliphatic group, benzyl, substituted benzyl, aromatic or substituted aromatic group)), -SH, -S(aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group) and -NH-C(=NH)-NH2. A substituted non-aromatic heterocyclic ring, benzylic group or aromatic group can also have an aliphatic or substituted aliphatic group as a substituent.
A substituted alkyl or aliphatic group can also have a non-aromatic heterocyclic ring, benzyl, substituted benzyl, aromatic or substituted aromatic group as a substituent. A
substituted non-aromatic heterocyclic ring can also have =O; =S, =NH or =N(aliphatic, aromatic or substituted aromatic group) as a substituent. A substituted aliphatic, substituted aromatic, substituted non-aromatic heterocyclic ring or substituted benzyl group can have more than one substituent.
In the structural formulas depicted herein, the single or double bond by which a chemical group or moiety is connected to the remainder of the molecule or compound is indicated by the following symbol:
,t n For example, the corresponding symbol in Structural Formula (V) or (VIII) indicates that the tricyclic ring system, which respresents Z in Structural Formula (I), is connected to the alkylene group in Structural Formula (I) by a single covalent bond between the alkylene group and the ring carbon in Ring C which is bonded to W.
A "subject" is preferably a mammal, such as a human, but can also be an animal in need of veterinary treatment, e.g., domestic animals (e. g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e. g., rats, mice, guinea pigs, and the like).
A "therapeutically effective amount" of a compound is a~ amount which results in the inhibition of one or more processes mediated by the binding of a chemokine to a receptor in a subject with a disease associated with aberrant leukocyte recruitment and/or activation. Examples of such processes include leukocyte migration, integrin activation, transient increases in the concentration of intracellular tree calcium [CaZ"]; and granule release of proinflammatory mediators. Alternatively, a "therapeutically effective amount" of a compound is a quantity sufficient to achieve a desired therapeutic and/or prophylactic effect, such as an amount which results in the prevention of or a decrease in the symptoms associated with a disease associated with aberrant leukocyte recruitment and/or activation.
The amount of compound administered to the individual will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
Typically, a therapeutically effective amount of the compound can range from about 0.1 mg per day to about 100 mg per day for an adult. Preferably, the dosage ranges from about 1 mg per day to about 100 mg per day. An antagonist of chemokine receptor function can also be administered in combination with one or more additional therapeutic agents, e.g. theophylline, G-adrenergic 5 bronchdilators, corticosteroids,'antihistamines, antiallergic agents, immunosuppressive agents (e. g., cyclosporin A, FK-506, prednisone, methylprednisolone) and the like.
The compound can be administered by any suitable 10 route, including, for example, orally in capsules, suspensions or tablets or by.parenteral administration.
Parenteral administration can include, for example, systemic administration, such as by intramuscular, intravenous, subcutaneous, or intraperitoneal injection.
15 The compound can also be administered orally (e. g., dietary), topically, by inhalation (e. g., intrabronchial, intranasal, oral inhalation or intranasal drops), or rectally, depending on the disease or condition to be treated. Oral or parenteral administration are preferred 20 modes of administration.
The compound can be administered to the individual ir.
conjunction with an acceptable pharmaceutical or physiological carrier as part of a pharmaceutical composition for treatment of HIV infection, inflammatory 25 disease, or the other diseases discussed above.
Formulation of a compound to be administered will vary according to the route of administration selected (e. g., solution, emulsion, capsule). Suitable carriers may contain inert ingredients which do not interact with the compound. Standard formulation techniques can be employed, such as those described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. Suitable carriers for parenteral administration include, for example, sterile water, physiological saline, bacteriostatic saline (saline containing about ;;.9% mg/ml benzyl alcohol), phosphate-buffered saline, Hank's solution, Ringer's-lactate and the like. Methods for encapsulating compositions (such as in a coating of hard gelatin cr cyclodextran) are known in the art ;Baker, et al., "Controlled Release of Biological Active Agents", John l0 Wiley and Sons, 1986).
The activity of compounds of the present invention can be assessed using suitable assays, such as receptor binding assays and chemotaxis assays. For example, as described in the Exemplification Section, small molecule antagonists of RANTES and MIP-la binding have been identified utilizing THP-1 cells which bind RANTES and chemotax in response to R.ANTES and MIP-la as a model for leukocyte chemotaxis.
Specifically, a high through-put receptor binding assay, which monitors lzsI-RANTES and lzsl_MIP-la binding to THP-1 cell membranes, was used to identify small molecule antagonists which block binding of RANTES and M1P-la.
Compounds of the present invention can also be identified by virtue of their ability to inhibit the activation steps triggered by binding of a chemokine to its receptor, such as chemotaxis, integrin activation and granule mediator release. They can also be identified by virtue of their ability to block RANTES and MIP-la mediated HL-60, T-cell, peripheral blood mononuclear cell, and eosinophil chemotactic response.
The compounds disclosed herein can be prepared accordingly to the schemes shown in Figures 1-3. The schemes are described in greater detail below.
Figure 1 is a schematic showing the preparation o~ the compounds represented by Structural Formula (I).
L', LZ and L' in Figure 1 are suitable leaving groups such as halogen; o-toluene sulfonate, mesylate, alkoxy and phenoxy. The other symbols are as defined above.
The reduction. reaction in Step 1 of Figure 1 is performed with a reducing agent such as or sodium borohydride or lithium aluminum hydride (LAH) in an inert solvent such as methanol or tetrahydrofuran (THF. The reaction is carried out at temperatures ranging from 0°C up to the reflux temperature and for 5 minutes to 72 h.
Compounds represented by formula II in Figure 1 can be prepared by procedures disclosed in JP 61/152673, U.S.
Patent 5089496, WO 89/10369, WO 92/20681 and WO 93/02081, the entire teachings of which are incorporated herein by reference.
A chlorination reaction in step 2 of Figure 1 can be performed with reagents such as thionyl chloride. The reaction can be carried out in an inert solvent such as methylene chloride at 0°C up to the reflux temperature for 5 minutes to 72 h. The hydroxy group can be also converted to other leaving groups by methods familiar to those skilled in the art.
The cyanatior. reaction in step 3 of Figure 1 can be carried out using reagents such as copper cyanide, silver cyanide or sodium cyanide in an inert solvent such as benzene or toluene. Reacton temperatures range from 0°C up to the reflux temperature for 5 minutes to 72 h. Compounds WO 99/37617 ~g PCT/US99/01265 represented by Formula V in Figure 1 can also be prepared by the procedures described in J. Med. Chem. 1994, 37, 804-810 and U.S. Patent 5672611, the entire teachings c which are incorporated herein by reference.
The alkylation reactions in steps 4 and 5 of Figure 1 can be carried out in a solvent such as acetone, methyl ethyl ketone, ethyl acetate, toluene, tetrahydrofuran (THF) or dimethylformamide (DMF) in the presence of a base such as potassium carbonate or sodium hydride and a catalyst IO such as an alkali metal iodide (when necessary}. The reaction temperature can range from room temperature up to the reflux temperature and for 5 minutes to 72 h.
The product of the synthetic scheme shown in Figure 1 can be decyanated using a reducing agent such as lithium aluminum hydride (LAH) in an inert solvent such as ether or tetrahydrofuran (THF) at 0°C up to the reflux temperature for the solvent used for 5 minutes to 72 h.
Figure 2 is a schematic showing the preparation of the compounds represented by Stuctural Formula (I) and II), wherein Z is represented by Structural Formulas (IV) and wherein Ring A in Z is substituted with - (CHz) t-COOH, - (CHZ) ~-COORZ° or - (CHZ) t-C (O) -NRzlR~2 .
In Figure 2, the hydrolysis reaction may be carried out in a mixture of aqueous alkali metal hydroxide solution and a solvent such as methanol, ethanol, tetrahydrofuran (THF) or dioxane at room temperature up to the reflux temperature for the solvent used~for 5 minutes to 72 h.
The acylation reaction can be carried out using dicyclohexylcarbodiimide (DCC) or (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (DEC) in a solvent such as tetrahydrofuran (THF), dimetrylformamide (DMF) or methylene chloride in the presence of a base such as pyridine or triethylamine (when necessary) at temperatures of 0 to 100°C for 5 minutes Lo 72 h.
Compounds represented by Structural Formulas (I) and (II), wherein Z is represented by Structural Formulas (XVI) , X is -CO-N(R~) - and R° is - (CHZ) S-COOH, - (CHz) S-COOR~°
or - (CHZ) S-C (O) -NR"R'2 can be prepared by suitable modification of the scheme shown in Figure 1. One modification utilizes the starting material shown in Figure 1, wherein X is -CO-NH-. The amide is then alkylated with L3- (CHZ) e-COOR'° using the alkylation procedures described above. L' is a suitable leaving group. The remainder of the synthesis is as described in Figures 1 and 2.
Figure 3 is a schematic showing the preparation of the compounds represented by Structural Formula (I) and (II), wherein Z is represented by Structural Formulas (VIII) and (XIII-(XVI) and wherein V is Wa.
The reduction of the cyano group to an amine in Figure 3 can be carried out using metal hydrides or by catalytic reduction processes. Suitable reducing agents include lithium aluminum hydride (LAH), diisobutyl aluminum hydride (DIBAL-H), borane-methyl sulfide complex or sodium borohydride. The reduction can be carried out in an inert solvent such as ether, tetrahydrofuran (THF), methylene chloride or methanol at -78°C up to the reflux temperature for 5 minutes to 72 h. It is also possible to isolate the corresponding imine intermediate, which can be converted to the amine using similar reduction processes.
Although Figures 1-3 show the preparation of compounds in which Rings A and B are phenyl rings, analogous compounds with heteroaryl groups for Rings A and B can be WO 99/37617 3o PCT/US99/O1Z65 prepared by using the starting materials with heteroaryl groups in the corresponding positions, which can be prepared according to methods disclosed in JP 6i/152673, U.S. Patent 5089496, WO 89/10369, WC 92/20681 and WO
93/02081.
The invention is illustrated by the following examples which are not intended to be limiting in any way.
EXEMPLIFICATION
Example 1 - Preparation of 4-(4-Chlorophenyl)1-[3-(5-cyano-5H-dibenzo[a,d]cycloheptene-5-yl)propyl]piperidin-4-of To a solution of 5H-dibenzo(a,d]cycloheptene-5-carbonitrile (described in J. Med Chem. 1994, 37, 804-810)(SOOmg) in DMF (lOml) were added 60% sodium hydride (110mg) and 1-bromo-3- chloropropane (0.30m1) and the mixture was stirred at room temperature for 1 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate.
The solvent was distilled off under reduced pressure to give 5-(3-chloropropy~-5H-dibenzo[a,d]cycloheptene-5-carbonitrile. Without purification, to a solution obtained chloride in DMF (lOml) were added 4-(4-chlorophenyl)-4- hydroxypiperidine (650mg), potassium carbonate (950mg), and potassium iodide (50mg) and the mixture was stirred at 70°C for 24 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:1) to give the titled compound (700mg) . 'H-NMR (CDC1,) d: l.z~-1.j4 ~~ri,m~ , 1.60-1.80(3H,m), 1.93-1.99(2H,m), 2.16-2.28(6H,m), 2 . 56-2.60 (2H,m) , 6.98 (2H, s) , 7.25-7.47 ClOH,m) , 8.00-8.03 (2H,m) . MS m/z: 469 (M+1) Example 2 - Preparation of 4-(4-Chlorophenyl)-1-[3-(5-cyano-10,11-dihydro-5H-dibenzo[a;d]cycloheptene-5-yl)propyl]piperidin-4-of Following the procedure of example l, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-carbonitrile, the titled compound was prepared. 1H-NMR (CDC1,) 8:
1.43-1.49(2H,m), 1.61-1.66(2H,m), 1.93-2.02(3H,m), 2.24-2.32(4H,m), 2.48-2.62(4H,m), 2.96-3.06(2H,m), 3.35-3.45 (2H,m) , 7.11-7.41 (lOH,m) , 7.93-7. 97 (2H,m) . MS
m/z: 471(M+1) Example 3 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenz[b,a]oxepin-11-yl)propyl]piperidin-4-0l Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 6,11-dihydrodibenz[b,e]oxepin-11-carbonitrile, the titled compound was prepared. 1H-NMR (CDC13) 8: 1.37-1.68(5H,m), 1.99-2.09(2H,m), 2.24-2.50(SH,m), 2.65-2.69(2H,m), 2.78-2.85(lH,m), 5.03(lH,d), 5.45(lH,d), 7.02-7.43(lOH,m), 7.82-7.86(lH,m), 7.95-8.00(lH,m). MS m/z: 473(M+1) Example 4 - Preparation of 1-[3-(11-Cyano-6,11-dihydrodibenz[b,e]oxepin-11-yl)propyl]-4-(4-fluorophenyl)piperidin-4-of Following the procedure of example 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-fluorophenyl)- 4-hydroxypiperidine, the titled compound was prepared. -H-NMR (CDC1~) ~: 1.40-1.68(4H;m), 1.88-2.08(3H,m), 2.29-2.50(5H,m), 2.63-2.67(2H,m), 2 . 77-2 . 84 ( 1H, m) , 5 . 03 ( 1H, d) , 5 . 44 ( 1H, d) , 6 . 95-7 . 46 ( lOH, m) , 7.81-7.85(lH,m), 7.94-7.99(lH,m). MS m/z: 457(M+1) Example 5 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-2-fluorodibenz[b,e]oxepin-11-yl)propyl]piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 6,11-dihydro-2-fluorodibenz[b,e]oxepin-11-carbonitrile, the titled compound was prepared. 1H-NMR (CDC13) 8:
1.37-1.69(SH,m). 1.98-2.09(2H,m), 2.25-2.48(SH,m), 2.65-2.70(2H,m), 2.78-2.87(lH,m), 5.01(lH,d), 5.42(lH,d), 6.99-7.11(3H,m), 7.25-7.43(6H,m), 7.54-7.59(lH,m), 7.92-7.95 (lH,m) . MS m/z: 491 (M+1) Example 6 - Preparation of 1-[3-(2-Bromo-11-cyano-6,11-dihydrodibenz[b,e]oxepin-11-yl)propyl]-4-(4-chlorophenyl)piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 2-bromo-6,11-dihydrodibenz[b,e]oxepin-11-carbonitrile, the titled compound was prepared. 1H-NMR tCDCl3) b:
1.37-1.69(SH,m), 1.97-2.09(2H,m), 2.24-2.48(SH,m), 2.66-2.85 (3H,m) , 5.00 (lH,d) , 5.43 .(lH,d) , 6.97-7.02 (2H,m) , 7.24-7.46 (7H,m) , 7.91-7.95 (2:-i,m) .
MS m/z: 551, 553(M+1) Example 7 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-2-methyldibenz[b,e]oxepin-11-yl)propyl]piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with IO 6,11-dihydro-2-methyldibenz[b,e]oxepin-11-carbonitrile, the titled compound was prepared. 'H-NMR (CDC13) b:
1 .40-1.70 (SH,m) , 1.98-2.09 (2H,m) , 2.25-2.52 (8H,m) , 2.68-2.73(2H,m), 2.81-2.90(lH,m), 5.00(lH,d), 5.44(lH,d), 6.98-7.43 (9H,m) , 7.63 (lH,d) , 7.94-7.98 (lH,m) . MS m/z:
487(M+1) Example 8 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-3,4-dichloro-6,11-dihydro-dibenz[b,e]oxepin-11-yl)propyl]piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 3,4-dichloro-6,11-dihydrodibenz[b,e]oxepin-11-carbonitrile, the titled compound was prepared. 1H-NMR (CDC13) 8:
1.40-1.71(SH,m), 2.00-2.10(2H,m), 2.28-2.50(SH,m), 2.65-2.85(3H,m), 5.04(lH,d), 5.46(lH,d), 6.99-7.03(lH,m), 7.26-7.44 (7H,m) , 7.91-7.95 (2H,m) . MS m/z: 541 (M+1) Example 9 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-2,3-methylenedioxydibenz[b,e]oxepin-11-yl)propyl]piperidin-4-of Following the procedure of example 1, b~~ replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 6,11-dihydro-2,3- methylenedioxydibenz[b,e]oxepin-11-carbonitrile, the titled compound was prepared. 'H-NMR
(CDC13) b: 1.60-1.90 (SH,m) , 2.30-2.50 (2H,m) , 2.80-3.30 (8H,m) , 5.05 (lH,d) , 5.45 (lH,d) , 6.02 (2H,brd) , 6.68(lH,s), 6.97-7.01(lH,m), 7.26-7.43(7H,m), 7.83-7. 87 (2H,m) . MS m/z: 517 (M+1) Example 10 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 6,11-dihydrodibenzo(b,e]thiepin-11-carbonitrile, the titled compound was prepared. 'H-NMR (CDC13) 8: 1.63-1.76(SH,m), 2.03-2.16 (2H,m) , 2.37-2.52 (4H,m) , 2.72-2.85 (3H,m) , 3.03-3.10 (lH,m) , 4.10 (iH,d) , 4.54 (lH,d) , 7.13-7.44 (lOH,m) , 7.81-7.87(2H,m). MS m/z: 489(M+1) Example 11 - Preparation of 1-(3-(11-Cyano-6,11-dihydrodibenzo(b,e]thiepin-11-yl)propyl]-4-phenylpiperidin-4-0l Following the procedure of example 10, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-hydroxy-4-phenylpiperidine, the titled compound was prepared.
1H-NMR (CDC1;) 8: 1.63-1.77 (SH,m) , 2.02-2.16 (2H,m) , 2.37-2.52(4H,m), 2.72-2.85(3H,m), 3.03-3.10(lH,m), 4 . 10 (1H, d) , 4 . 55 (1H, d) , 7 . 13-7 . 52 (lOH, m) , 7 . 81-7 . 80 (2H, m) .
MS m/z: 455(M+1) 5 Example 12 - Preparation of 4-(4-Bromophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of Following the procedure of example 10, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 10 4-(4-bromophenyl)-4- hydroxypiperidine, the titled compound was prepared. 'H-NMR (CDC13) b: 1.64-1.82 (SH,m) , 2.02-2.12 (2H,m) , 2.32-2.48 (4H,m) , 2.69-2.85 (3H,m) , 2.99-3.09(lH,m), 4.07(lH,d), 4.50(lH,d), 7.11-7.46(lOH,m), 7.79-7.86(2H,m). MS m/z: 533, 535(M+1) 15 Example 13 - Preparation of 1-(3-(2-Bromo-11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]-4-(4-chlorophenyl)piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 20 2-bromo-6,11-dihydrodibenzo[b,e]thiepin-11-carbonitrile, the titled compound was prepared.lH-NMR (CDC1,) 8:
1. 63-1.78 (SH,m) , 2 .03-2.14 (2H,m) , 2.35-2 .52 (4H,m) , 2.72-2.80(3H,m), 3.00-3.10(lH,m), 4.15(lH,brd), 4.50(lH,d), 7.07-7.45(lOH,m), 7.73-7.81(lH,m), 7.95(lH,d). MS m/z: 567, 25 569 (M+1) WO 99!37617 36 PCT/US99/O1Z65 Example 14, 15 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-5-oxodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 6,11-dihydro-5-oxcdibenzo[b,e]thiepin-11-carbonitrile, the titled compound :~~as prepared. The diastereomers were separated by silica gel chromatography. isomer 1 'H-NMR
(CDC13) 8: 1.20-1.35(lH,m), 1.63-1.69(4H,m), 2.04-2.84(lOH,m), 4.21(lH,d), 4.31(lH,d), 7.18-7.65(9H,m), 8.03-8. 13 (3H,m) . MS m/z: 505 (M+1) isomer 2 1H-NMR (CDC13) d:
1.25-1.38(lH,m), 1.65-2.15(6H,m), 2.28-2.82(BH,m), 4.65(lH,d), 4.82(lH,d), 7.27-7.56(9H,m), 7.92-8.00(3H,m).
MS m/z: 505 (M+1) Example 16 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-5,5-dioxodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 6,11-dihydro-5,5-dioxodibenzo[b,e]thiepin-11-carbon~trile, the titled compound was prepared. 'H-NMR (CDC13) ~:
1.40-2.72(l4H,m), 3.08-3.22(lH,m), 4.58(lH,d), 5.58(lH,d), 7.29-7.58(9H,m), 7.99-8.13(3H,m). MS m/z: 521(M+1) WO 99/37617 3,~ PCTlUS99/O1Z65 Example 17 - Preparation of 4-(4-Chlorophenyl)-1-[3-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of To a solution of 4-(4-chlorophenyl)-1-[3-(11-cyano-6,11- dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of (430mg) in THF lOml) was added 1M
lithium aluminum hydride THF solution (1.5m1) and the mixture was heated to reflux for 3 hours. The reaction mixture was cooled with ice, water (0.06m1), then 15%
aqueous sodium hydroxide (0.06m1), then water (0.18m1) were added carefully. The granular salt was filtered off and the filtrate was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:1) to give the titled compound (280mg) . 1H-NMR (CDC13) b: 1.55-1.80 (4H,m) , 2.03-2.16(2H,m), 2.25-2.52(6H,m), 2.72-2.80(2H,m), 3.90(lH,brs), 4.48(lH,brt), 4.68(lH,brs), 6.96-7.45(l2H,m).
MS m/z: 464 (M+1) Example 18 - Preparation of 4-(4-Chlorophenyl)-1-[3-(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-yl)propyl]piperidin-4-0l Following the procedure of example 17, but replacing 4-(4-chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of with 4-(4-chlorophenyl)-1-[3-(5-cyano-10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-yl)propyl]piperidin-4-ol, the titled compound was prepared. 'H-NMR (CDC1;) b:
1.40-1.58(2H,m), 1.62-1.71(2H,m), 1.98-2.20(4H,m), 2.30-2.42 (4H,m) , 2.67-2.78 (2H,m) , 2.95-3.08 (2H,m) , WO 99/37617 3g PCT/US99/01165 3 .30-3 .44 (2H,m) , 4.01 (1H, t) , 7.10-7.46 (l2H,m) . MS m/z:
446 (M+1) Example 19 - Preparation of 4-(4-Chlorophenyl)-1-[3-(6,11-dihydrodibenz[b,e]oxepin-11-yl)propyl]piperidin-4-of Following the procedure of example 17, but replacing 4-(~-crlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,e]t~iepin-11-yl)propyl]piperidin-4-of with 4-(4-chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenz[b,e]ox epin- 11-yl)propyl]piperidin-4-ol,. the titled compound was prepared. 1H-NMR {CDC13) 8: 1.36-1.49 (2H,m) , 1.58-1.67(2H,m), 1.95-2.33(8H,m), 2.63-2.68(2H,m), 3 .74 (1H, t) , 4.95 (1H, d) , 5.48 (lH,d) , 6.95-7.39 (l2H,m) . MS
m/z: 448{M+1) Example 20 - Preparation of 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-11-iminodibenzo[b,e]thiepin-11-yl)propyl]
piperidin-4-of To a solution of 4-(4-chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,elthiepin-11-yl)propyl]piperidin-4-of (1.92g) in dichloromethane (30m1) at -78°C was added 1M
diisobutyl aluminum hydride dichloromethane solution (lOml). The reaction mixture was warmed to room temperature, and stirred for 30 minutes. Water and dichloromethane were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate.
The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate to give the titled compound (1.16g).
1H-NMR (CDC13) 8: 1.65-1.80 (SH,m) , 2.02-2.18 (2H,m) , 2.45-2.60 (6H,m) , 2.78-2.86 (2H,m) , 3.82 {lH,d) , 4.25 (lH,d) , 7.05-7.45(l2H,m), 8.28(lH,brs). MS m/z: 491(M+1) Example 21 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-aminomethyl-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of To a solution of 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-11-iminodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of (600mg) in methanol (15m1) was sodium borohydride (220mg), and the mixture was stirred at room temperature for 10 hours. The solvent was distilled off under reduced pressure. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced to give the titled compound (600mg). MS
m/z:493(M+1) Example 22 - Preparation of Phenyl N- [2- (3- [4- (4-chlorophenyl)- 4-hydroxypiperidino]propyl]-2-(6,11-dihydrodibenzo[b,e]thiepin- 11-yl)ethyl] carbamate To a solution of 4-(4-chlorophenyl)-I-[3-(11-aminomethyl-6,1i-dihydrodibenzo[b,e]thiepin-11-yl)propyl] piperidin-4-of (610mg) in THF (20m1) was triethylamine (0.2m1) and phenyl chlorocarbonate (0.16m1) at 0°C, and the mixture was stirred for 1 hours. Water and ethyl acetate were added to the reacticn mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate.
$O
The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate to give the titled compound (400mg).
1H-NMR (CDC13) b: 1.40-2.90 (lSH,m) , 4.05-4. i2 (2H,m) , 4.38(lH,d), 4.50-4.60(lH,m), S.98(lH,brs), 6.96-7.54(l7H,m). MS m/z: 613(M+1) Example 23 - Preparation of 1-[2-[3-[4-(4-chiorophenyl)-4-hydroxypiperidino]propyl]-2-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)ethyl]-3-(hydroxypropyl)urea To a solution phenyl N- [2- [3- [4- (4-chlorophenyl) -4-hydroxypiperidino]propyl]-2-(6,1I-dihydrodibenzo[b,e]thiepin-11-yl)ethyl] carbamate (300mg) in DMF (lOml) were added 3-amino-1-propanol (70mg), potassium carbonate (130mg) and the mixture was stirred at room temperature for 16 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-methanol (9:1) to give the titled compound (200mg).
1H-NMR (CDC1;) d: 1.40-1.70 (6H,m) , 2.01-2. 08 (2H,m),, 2 . 30-2 . 63 (8H, m) , 3 . 12 (2H, q) , 3 .42 (2H, t) , 4 . 00-4 . 12 (2H, m) , 4.22-4.28(2H,m), 4.82(lH,brt), 4.99(lH,brs), 6.98-7.45(l2H,m).MS m/z: 594(M+1) Example 24 - Preparation of 4-(4-Chlorophenyl)-1-[3-(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-yl)-3-propioyl]piperidin-4-of To a solution 10,11-dihydro-5H-dibenzo[a, d]
cycloheptene-5-carbonitrile (500mg) in THF (5m1) was added 1.6M n-butyl lithium hexane solution (1:8m1) at 0°C. The mixture was warmed to room temperature, and stirred for 20 minutes. Tc the reaction mixture cooled to 0°C was added ethyl 3-(4-(4-chlorophenyl)-4- hydroxypiperidine-1-yl)propionate (310mg) dropwise as THF solution (2m1), and the mixture was warmed to room temperature, and stirred for 30 minutes. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:1) to give the titled compound (380mg) . 1H-NMR (CDC13) 8:
1.57-1.62 (2H,m) , 1.91-2.01 (3H,m) , 2.27-2.84 (lOH,m) , 3.30-3.44(2H,m), 4.65(lH,s), 7.10-7.38(l2H,m).
MS m/z: 460{M+1) Examples 28 - 59 can be prepared by methods set forth in the schemes in Figure 1-3 and the procedures described above.
Example 60 Membrane Preparations for Chemokine Binding and Binding Assays Membranes were prepared from THP-1 cells (ATCC #TIB2G2).
Cells were harvested by centrifugation, washed twice with PBS (phosphate-buffered saline), and the cell pellets were frozen at -70 to -85°C. The frozen pellet was thawed in ice-cold l~,rsis buffer consisting of 5 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethane-sulfonic acid) pH 7.5, 2 mM EDTA (ethylenediaminetetraacetic acid), 5 ~cg/ml each aprotinin, leupeptin, and chymostatin (protease inhibitors), and 100 ~cg/ml PMSF (phenyl methane sulfonyl fluoride - also a protease inhibitor), at a concentration of 1 to 5 x 10' cells/ml. This procedure results in cell lysis. The suspension was mixed well to resuspend all of the frozen cell pellet. Nuclei and cell debris were removed by centrifugation of 400 x g for 10 minutes at 4°C.
The supernatant was transferred to a fresh tube and the membrane fragments were collected by centrifugation at 25,000 x g for 30 minutes at 4°C. The supernatant was aspirated and the pellet was resuspended in freezing buffer consisting of 10 mM HEPES pH 7.5, 300 mM sucrose, l~g/ml each aprotinin, leupeptin, and chymostatin, and 10 ~cg/ml PMSF (approximately 0.1 ml per each I08 cells). All clumps were resolved using a minihomogenizer, and the total protein concentration was determined using a protein assay kit (Bio-Rad, Hercules, CA, cat #500-0002). The membrane solution was then aliauoted and frozen at -70 to -85°C
until needed.
~3 Binding Assays utilized the membranes described above.
Membrane protein (2 to 20 ~.g total membrane protein) was incubated with 0.1 to 0.2 nM izSl-labeled RANTES or MIF-icx with or without unlabeled competitor (RANTES or MIP-la) or various concentrations of compounds. The binding reactions were performed in 60 to laa ul of a binding buffer consisting of 10 mM uEPES pH 7.2, 1 mM CaClz, 5 mM MgClz, and 0.5% BSA (bovine serum albumin), for 60 min at room temperature. The binding reactions were terminated by harvesting the membranes by rapid filtration through glass fiber filters (GF/B or GF/C, Packard) which were presoaked in 0.3% polyethyleneimine. The filters were rinsed with approximately 600 ~.1 of binding buffer containing 0.5 M
NaCl, dried, and the amount of bound radioactivity was determined by scintillation counting in a Topcount beta-plate counter.
The activities of test compounds are reported in the Table below as ICSO values or the inhibitor concentration required for 50% inhibition of specific binding in receptor G
binding assays using 12~'I-RANTES or lzsMIP-la as ligand and THP- .1 cell membranes. Specific binding is defined as the total binding minus the non-specific binding; non-specific binding is the amount of cpm still detected in the presence of excess unlabeled Rantes or l2sMIP-la.
Table BIOLOGICAL DATA
Example ICSo (ACM) 1 0.088 2 0.052 3 0.11 4 0.39 5 0.19 6 0.30 7 0.38 10 0.097 12 0.099 13 0.38 14 0.28 15 0.61 16 0.079 17 0.070 18 0.055 19 0.059 22 0.69 23 2.2 24 0.16 25 0.13 26 0.61 27 0.48 4~
Those skilled in the art will be able to recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
AND METHODS OF USE THEREFOR
RELATED APPLICATIONS
This application is a continuation-in-part of U.S.
Serial No. 09/010,321, filed January 21, 1998, which is a continuation-in-part of U.S. Serial No. 08/891,518, filed July 11, 1997, which claims priority to U.S. Provisional Application Serial No. 60/021,716, filed July 12, 1996, the entire teachings of which are hereby incorporated by reference.
BACKGROUND OF THE INVENTION
Chemoattractant cytokines or chemokines are a family of proinflammatory mediators that promote recruitment and activation of multiple lineages of leukocytes and lymphocytes. They can be released by many kinds of tissue cells after activation. Continuous release of chemokines at sites of inflammation mediates the ongoing migration of effector cells in chronic inflammation. The chemokines characterized to date are related in primary structure.
They share four conserved cysteines, which form disulfide bonds. Based upon this conserved cysteine motif, the family is divided into two main branches, designated as the C-X-C
chemokines (a-chemokines), and the C-C chemokines (~i-chemokines), in which the first two conserved cysteines are separated by an intervening residue, or adjacent respectively (Baggiolini, M. and Dahinden, C. A., Imnrurtology Today, 15:127-133 (1994) ) .
WO 99/37617 PC'T/US99/01265 The C-X-C chemokines include a number o~ potent chemoattractants and activators of neutrophils, such as interleukin 8 (IL-8), PF4 and neutrophil-activating peptide-2 (NAP-2). The C-C chemokines include nANTES
(Regulated on 8ctivation, Normal T Expressed and Secreted), the macrophage inflammatory proteins la and la (MIP-la and MIP-1(3), and human monocyte chemotatic proteins 1-3 (MCP-1, MCP-2, MCP-3), which have been characterized as chemoattractants and activators of monocytes or lymphocytes but do not appear to be chemoattractants for neutrophils.
Chemokines, such as RANTES and MIP-la, have been implicated in a wide range of human acute and chronic inflammatory diseases including respiratory diseases, such as asthma and allergic disorders.
The chemokine receptors are members of a superfamily of G protein-coupled receptors (GPCR) which share structural features that reflect a common mechanism of action of signal transduction (Gerard, C. and Gerard, N.P., Annu Rev. Immunol., 12:775-808 (1994); Gerard, C. and Gerard, N. P., Curr. Opin. Immunol., 6:140-145 (1994)).
Conserved features include seven hydrophobic domains spanning the plasma membrane, which are connected by hydrophilic extracellular and intracellular loops. The majority of the primary sequence homology occurs in the hydrophobic transmembrane regions with the hydrophilic regions being more diverse. The first receptor for the C-C
chemokines that was cloned and expressed binds the chemokines MIP-la and RANTES. Accordingly, this MIP-la/RANTES receptor was designated C-C chemokine receptor 1 (also referred to as CCR-1; Neote, K., et al., Cell, 72:415-425 (1993); Horuk, R. et al., WO 94/11504, May 26, 1994; Gao, J.-I. et al., J. Exp. Med., 177:1421-1427 (1993)). Three new receptors have been characterized which bind and/or signal i:i response to RP.IvTES : CCR3 med~.ates binding and signaling of chemokines including eotaxin, RANTES, and MCP-3 (Ponath et al., J. Exp. Med., 183:2437 (1996)), CCR4 binds chemokines including RANTES, MIP-ia, and MCP-1 (Power, et al., J. Biol. Chem., 276:19495 (1995)), and CCR5 binds chemokines including MIP-la, RANTES, and MIP-1(3 (Samson, et al., Biochem. 35: 3362-3367 (1996)). RANTES is a chemotactic chemokine for a variety of cell types, including monocytes, eosinophils, and a subset of T-cells. The responses of these different cells may not all be mediated by the same receptor, and it is possible that the receptors CCR1, CCR4 and CCR5 will show some selectivity in receptor distribution and function between leukocyte types, as has already been shown for CCR3 (Ponath et al.). In particular, the ability of RANTES to induce the directed migration of monocytes and a memory population of circulating T-cells (Schall, T. et al., Nature, 347:669-71 (1990)) suggests this chemokine and its receptors) may play a critical role in chronic inflammatory diseases, since these diseases are characterized by destructive infiltrates of T cells and monocytes.
Many existing drugs have been developed as antagonists of the receptors for biogenic amines, for example, as antagonists of the dopamine and histamine receptors. No successful antagonists have yet been developed to the receptors for the larger proteins such as chemokines and CSa. Small molecule antagonists of the interaction between C-C chemokine receptors and their ligands, including RANTES
and MIP-la, would provide compounds useful for inhibiting harmful inflammatory processes "triggered" by receptor ligand interaction, as well as valuable tools for the investigation of receptor-ligand inter~~tions.
SUMMARY OF THE INVENTION
rt has now been found that a number of small organic molecules are antagonists of chemokine receptor function and can inhibit leukocyte activation and/or recruitment.
An antagonist of chemokine receptor function is a molecule which can inhibit the binding of one or more chemokines, including C-C chemokines such as RANTES and/or MIP-la, to one or more chemokine receptors on leukocytes and/or other cell types. As a consequence, processes and cellular responses mediated by chemokine receptors can be inhibited with these small organic molecules. Based on this discovery, a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation is disclosed. The method comprises administering to the subject a therapeutically effective amount of a compound cr small organic molecule which is an antagonist of chemokine receptor function. Compounds or small organic molecules which have been identified as antagonists of chemokine receptor function are discussed in detail hereinbelow, and can be used for the manufacture of a medicament for treating or for preventing a disease associated with aberrant leukocyte recruitment and/or activation. The invention also relates to the disclosed compounds and small organic molecules for use in treating or preventing a disease associated with aberrant leukocyte recruitment and/or activation. The invention also includes S
pharmaceutical compositions comprising one or_ more of the compounds or small organic molecules which have been identified herein as antagonists of chemokine function and a suitable pharmaceutical carrier. The invention further 5 relates to novel compounds which can be~used to treat an individual with a disease associated with aberrant leukocyte recruitment and/or activation.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is a schematic showing the preparation of the 10 compounds represented by Structural Formulas (I).and (II).
Figure 2 is a schematic showing the preparation of the compounds represented by Structural Formula ((I) and II), wherein Z is representea b1 St ~~crural Formulas (IV) and wherein Ring A in Z is substituted with 15 - (CH2) t-COOH, - (CHZ) t-COOR2° or - (CH2) t-C (O) -NRZIRzz Figure 3 is a schematic showing the preparation of the compounds represented by Structural Formula (I) and (II), wherein Z is represented by Structural Formulas (VIII) and (XI II ) - (XVI ) and wherein V is Wa .
20 Figure 4A - 4F show the structures of a number of exemplary compounds of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to small molecule compounds which are antagonists of chemokine receptor 25 function. Accordingly, processes or cellular responses mediated by the binding of a chemokine to a receptor can be inhibited (reduced or prevented, in whole or in part), including leukocyte migration, integrin activation, transient increases in the concentration of intracellular free calcium [Ca'-] i, and/or granule rel ease of proinflammatory mediators.
The invention further relates to a method of treatment, including prophylactic and therapeutic treatments, of a disease associated with aberrant leukocyte recruitment and/or activation or mediated by chemokines or chemokine receptor function, including chronic irflam«;atory disorders characterized by the presence of RANTES, MI.-la, MCP-2, MCP-3 and/or MCP-4 responsive T cells, monocytes and/or eosinophils; including but not limited to diseases such as arthritis (e. g., rheumatoid arthritis), atherosclerosis, arteriosclerosis, ischemia/reperfusion injury, diabetes mellitus (e. g., type 1 diabetes mellitus), psoriasis, multiple sclerosis, inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, rejection of transplanted organs and tissues (i.e., acute allograft rejection, chronic allograft rejection), graft versus host disease, as well as allergies and asthma. Other diseases associated with aberrant leukocyte recruitment and/or activation which can be treated (including prophylactic treatments) with the methods disclosed herein are inflammatory diseases associated with Human Immunodeficiency Virus (HIV) infection, e.g., AIDS
associated encephalitis, AIDS related maculopapular skin eruption, AIDS related interstitial pneumonia, AIDS related enteropathy, AIDS related periportal hepatic inflammation and AIDS related glomerulo nephritis. The method comprises administering to the subject in need of treatment an effective amount of a compound (i.e., one or more compounds) which inhibits chemokine receptor function, inhibits the binding of a chemokine to leukocytes and/or other cell types, and/or which inhibits leukocyte migration to, and/or activation at, sites of inflammation. According to the method, chemc~cine-mediated chemotaxis and/or activation of pro-~;lammatory cells bearing receptors for chemokines can be inhibited. As used herein, ~~pro-inflammatory cells" includes but is not limited to leukocytes, since chemokine receptors may be expressed on other cell types, s;~ch as neurons and epithelial cells.
In one embodiment of the present invention, the antagonist of chemokine receptor function is represented by Structural Formula (I):
Z Y C X-N
~.~n M
(I) Z is a cycloalkyl or non-aromatic heterocyclic ring fused to one or more carbocyclic aromatic rings and/or heteroaromatic rings.
Y is a covalent bond, -O- or -CO-.
n is an integer from one to about five. n is preferably one, two, or three.
X is a covalent bond or -CO-.
M is >NR2 or >CR1R2. Preferably, M is >C (OH) Rz.
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group). Preferably, R: is -H
or -OH.
Rz is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a a WO 99/37617 PCT/US99/01265 benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group. Preferably, RZ is an aromatic or a substituted aromatic group.
In a preferred embodiment, -X- and -Y- in Structural Formula (I) are each a covalent bond and the antagonist of chemokine receptor function is a compound represented by Structural Formula (II):
Cu~~
Z C ~tr--N M
(II) Z, n and M are as described above for Structural Formula (I) .
In another preferred embodiment, -X- is a covalent bond, -Y- is -CO- and the antagonist of chemokine receptor function is a compound represented by Structural Formula (III) O
Z/ \ (C
~~r-- M
(III) Preferably, Z is a tricyclic ring system comprising two carbocyclic aromatic groups fused to a seven or eight membered cycloalkyl group or to a non-aromatic heterocyclic ring. In one example, Z is represented by Structural Formula (IV) !~ I C I
(IV) The phenyl rings in Structural Formula (IV), labeled with an "A" and "B", are referred'to herein as "Ring A" and "Ring B", respectively. The central ring, labeled with a "C", is referred to as "Ring C" and can be, for example a six, seven or eight membered non-aromatic carbocyclic ring (e. g., a cycloheptane or cyclooctane ring) or a non-aromatic heterocyclic ring. When Ring C is a non-aromatic heterocyclic ring, it can contain one or two heteroatoms such as nitrogen, sulfur or oxygen. When Z is represented by Structural Formula (IV), the tricyclic ring system is connected to Y in Structural Formula (I) by a single covalent bond between Y and a ring atom in Ring C.
Ring A and/or Ring B can be unsubstituted.
Alternatively, Ring A and/or Ring B can have one or more substituents. Suitable substituents are as described hereinbelow for substituted aromatic groups. In one example, Ring A or Ring B is substituted with -(CHZ)t-COON, - (CHZ) C-COOR'° or - (CHZ) C-C (O) -NRZ1R22.
t is an integer from zero to about 3.
RZ°, Rz= or RZ2 are independently -H, an aliphatic group a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or -NHC(O)-O-(non-aromatic 5 heterocyclic group). In addition, R'1 and R", taken together with the nitrogen atom to which they are bonded, can form a non-aromatic heterocyclic ring.
Ring C optionally contains one or more additional substituents. When Ring C is a non-aromatic carbocyclic 10 ring, suitable substituents are as described hereinbelow for substituted aliphatic groups. When Ring C contains one or more heteroatoms, suitable substituents are as described below for non-aromatic heterocyclic rings. Preferably, Ring C is unsubstituted or substituted with an electron withdrawing group. Suitable electron withdrawing groups include -CN, alkylsulfonyl, carboxamido, carboxylic alkyl esters, -NO2 and halogens (e. g., -Br and -C1).
Alternatively, Ring C is substituted with a group selected from -CH2-NR11R1', -CHZ-OR11, -CH2-NH-CO-NR11R1~, -CH2-O-CO-NR'1R1'.
Ril and R'2 are independently -H, an aliphatic group a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), or NHC (O) -O- (aromatic group) . In addition, R'1 and Rlz, taken together with the nitrogen atom to which they are bonded, can form a non-aromatic heterocyclic ring.
Examples of suitable tricyclic rings systems represented by Structural Formula (IV) are provided by Structural Formula (V)-(VIII), shown below:
\ x, \ \ x, \
A I B I A I B
/ / ~ /
w ,~ W f (V) (VI) Xi ~ ~ X~
I A I B I A I B
/ / / /
f Wa (VII) We f (VIII}
Xl is a chemical bond, -S-, -CHZ- or -CHZS- .
Preferably, X1 is -S- in Structural Formulas (V) and (VII).
Preferably, X1 is -CHZS- in Structural Formulas (VI) and (VIII) .
W is -H or an electron withdrawing group, as described above for Structural Formula (IV). A preferred electron withdrawing group is -CN.
Wa is a group selected from -CH2-NR1'R12, -CHZ-OR11, -CI-:~-NH-CO-NR=iR=' or -CHZ-O-CO-NRllR~z. R1'- and R=' are as defined in Structural Formula (IV).
Ring A and Ring B in Structural Formulas (V)-(VIII) are as described above in Structural Formula (IV).
Other examples of suitable tricyclic ring systems represented by Structural Formula (IV) are shown below in Structural Formulas (IX)-(XII), (XIIa), (XIIb) an (XIIc):
W W iA o~ iB
(IX) (X) Rc~ p A NC I B
A C B
/ / / /
(XI) (XII) \ ~°2 \
A C B I A C I B
/ / / /
(XIIa) (XIIb) A C I B
/ /
(XIIc) Rings A-C in Structural Formulas (IX)-(XII), (XIIa), (XIIb) and (XIIc) are as described for Structural Formula (IV) .
R_ is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group; a benzyiic group or a substituted benzylic group.
Preferably, R~ is a substituted C1-C20 aliphatic group, a C10-C20 aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group or a substituted benzylic groin. T~ one example, R, is - (CHI) S-COON, - (CH2) ~-COOR" or - (CH. 1 =-C (O) -NR31R3z .
s is an integer from zero to about 3.
R'°, R'1 and R'2 are independently -H, an aliphatic group a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or -NHC(O)-O-(non-aromatic heterocyclic group) . In addition, R31 and R32, taken together with the nitrogen atom to which they are bonded, can form a non-aromatic heterocyclic ring.
Preferred examples of tricyclic ring systems represented by Structural Formulas (IX)-(XII),(XIIa), (XIIb) and (XIIc) are shown below in Structural Formulas (XIT_I) - (XVI) , (XVIa) , (XVIb) and (XVIc) WO PC1'/US99/OiZ6S
\ \ \ \
O
I I B I A I B
.A
/ / / /
V ~~ V
(XIII) (XIV) O
IA IB iA I B
/ / / /
V \~ V ~' (XV) (XVI) \ so \ \so2 ,\
A I B I A I B
/ / / /
V ~ (XVIb) v \~ (XVIa) A B
/ /
v ~ (XVIc) 1$
V is W or Wa, which are as described above for Structural Formula (V) - (VIII) .
In another preferred embodiment, Z is a tricyclic ring system comprising one or more heteroaromatic groups fused to a seven or eight membered cycloalkyl group or to a non-aromatic heterocyclic ring. Examples are represented by Structural Formulas (XVII)-(XXI), (XXIa), (XXIb) and (XXIc) AI I B
w~~,~' we f b (XVII) . (XVIII) AI I B
wti ~~ (XIX) ~yb ,/
J
( Rcv i~
B
We ~~' (XXIa) Wb ~ (XXIb) RcN
B
W ti ~ (XXIC) Ring A in Structural Formulas (XVII)-(XXI), (XXIa), (XXIb) and (XXIc) is a substituted or unsubstituted aromatic group.
Ring B in Structural Formulas (XVII)-(XXI), (XXIa), (XXIb) and (XXIc) is a substituted or unsubstituted heteroaryl group.
W,. is -H, -CN, -CHz-NR'1R1°, -CH2-OR'1, -CH2-NH-CO-NRllRlz -CHZ-O-CO-NR'1R1=. Rl' and Rw are as defined above for Structural Formula (IV).
In yet another preferred embodiment, the antagonist of chemokine function is a compound represented by Structural Formula (XXII and (XXIII):
X~ \ \ X~
A I B A I B
/ / / /
(CH z)\ W (CH z)\
M M
(XXII) (XXIII) In Structural Formulas (XXII) and (XXIII), X1 is as defined above for Structural Formulas (V) and (VI); n is an integer from two to five; W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl.
In Structural Formulas (XXII) and (XXIII), Ring A is substituted with Re and R9, wherein Re and R9 are independently -H, a halogen, alkoxy or alkyl, or, taken together with ring A, form a naphthyl group. M is >N(alkanoyl), >N(aroyl), >N(aralkoyl), >N(alkyl), >N(aralkyl), >N(cycloalkyl), >C(OH)(aryl) or >CH(heteroaryl).
The present invention also includes novel compounds represented by Structural Formulas (II) and (III).
In one embodiment, the novel compounds are represented by Structural Formulas (II) and (III) wherein Z is a group in which one or more heteroaromatic rings are fused to a cycloalkyl ring or a non-aromatic heterocyclic ring. Each ring in Z is independently substituted or unsubstituted.
Examples of suitable Z groups are represented by Structural Formulas (XVII ) - (XXI ) , (XXIa) , (XXIb) and (XXIc ) . Ring A, Ring B, M, Wb, R:, Rz, R~ and n are as described in StrucLUral Formulas (XVII) through (XXIc).
In another embodiment, the novel compounds are represented by Structural Formulas (II) and (III) have a Z
group represented by Structural Formulas (V) and (VI). At least one of Ring A or Ring B is substituted. M, W, R:, Rz and n are as described in Structural Formulas (v) and (VI).
In another embodiment, the novel ccmpounds represented by Structural Formulas (II) and (III) have a Z group represented by Structural Formulas (VII) and (VIII). Ring A, Ring B, M, Wa, R1, R2 and n are as described in Structural Formulas (VII) and (VIII).
In another embodiment, the novel compounds represented by Structural Formulas (II) and (III) have a Z group represented by Structural Formulas (XIII)-(XVI), (XVIa), (XVIb) and (XVIc) . Ring A, Ring B, M, R1, R2, R~ and n are as described in Structural Formulas (XIII) through (XVIc).
V is -CN, -CH2-NRl'Rl~, -CH2-OR'1, -CH2-NH-CO-NR'1R", -CH--O-CO-NR==R='. R-- and Ri' are as def fined above for Structural Formula (IV).
In another embodiment, the novel compounds represented by Structural Formulas (II) and (III) have a Z group represented by Structural Formula (XVI). Ring A, Ring B, M, R., R~, and n are as described in Structural Formula (XVI). V is -H and R~ is a C10-C20 aliphatic group, a substituted C10-C20 aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group or a substituted benzylic group. In one example, R_ is - (CHz) $-COOH, - (CHz) S-COOR3° or - (CHz) S-C (O) -NR'iR'~, wherein s, R'°, R'1 and R'Z are as desribed above. Preferably, R~ is an aromatic group, a substituted aromatic group, a benzylic group or a substituted benzylic group.
In yet another embodiment, the novel compounds represented by Structural Formula (II) and (III) have a Z
group represented by Structural Formulas (XXII) and (XXIII). Ring A, Ring B, M, W, and r. are as described in Structural Formulas (XXII) through (XXIII). Re and R9 are independently a halogen, alkoxy or alkyl, or, taken together with ring A, form a naphthyl group.
Also included in the present invention are physiologically acceptable salts of the compounds represented by Structural Formulas (I) through (XXIII).
Salts of compounds containing an amine or other basic group can be obtained, for example, by reacting with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like. Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like. Salts of compounds containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base, for example, a hydroxide base. Salts of acidic functional groups contain a countercation such as sodium, potassium and the like.
As used herein, aliphatic groups include straight chained, branched or cyclic C~-Ce hydrocarbons which are completely saturated or which contain one or more units of unsaturation.
WO 99/37617 2o PCT/US99/OtZ65 An "alkyl group" is a saturated aliphatic group, as defined above. The term "alkoxy" refers to an alkyl ether chain with ar. alkyl group. "Alkanoyl" refers to alkyl substituted carbonyl; "aralkanoyl" refers to phenyl-alkyl-CO- and "aroyl" refers to arylcarbonyl including benzoyl, naphthoyl and the like. The term "halogen" means fluoro, chloro, bromo and iodo. The term "aryl", as opposed to the term "aromatic group", means phenyl. The term "substituted phenyl" means aryl substituted by alkyl, halogen, alkoxy, vitro, amino, acetamido, cyano and trifluoromethyl and naphthyl.
"Aralkyl" means -(CHZ)X-phenyl, wherein x is an integer from one to four including benzyl. It is noted that the terms "aromatic group", "carbocylic aromatic group" and "heterocyclic aromatic group" are defined below and have different meanings from the term "aryl".
Aromatic groups include carbocyclic aromatic groups such as phenyl, 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthacyl, and heterocyclic aromatic groups such as N-imidazolyl, 2-imidazole, 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidy, 4-pyrimidyl, 2-pyranyl, 3-pyranyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-pyrazinyl, 2-thiazole, 4-thiazole, 5-thiazole, 2-oxazolyl, 4-oxazolyl and 5-oxazolyl.
Aromatic groups also include fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings. Examples include 2-benzothienyl, 3-benzothienyl, 2-benzofuranyl, 3-benzofuranyl, 2-indolyl, 3-indolyl, 2-quinolinyl, 3-quinolinyl, 2-benzothiazole, 2-benzooxazole, 2-benzimidazole, 2-quinolinyl, 3-quinolinyl, 1-isoquinolinyl, 3-quinolinyl, 1-isoindolyl, 3-isoindolyl, and acridintyl. Also included within the scope of the term "aromatic group", as it is used herein, is a group in which one or more carbocyclic aromatic rings and/or heteroaromatic rings are fused to a cycloalkyl or non-aromatic heterocyclic ring. Examples include decalin, phthalimido, benzodiazepines, benzooxazepines, benzooxazines, phenothiazines, and groups represented by the following structural formulas:
5 \ \ \
o / 5 I / , .
or WO 99!37617 PCT/US99/01165 Non-aromatic heterocyclic rings are non-aromatic carbocyclic rings which include one or more heteroatoms such as nitrogen, oxygen or sulfur in the ring. The rinc can be five, six, seven or eight-membered. Examples include 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahyrothiophenyl, 3-tetrahyrothiophenyl, 2-morpholirc, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyi, 4-piperidinyl and 4-thiazolidinyl.
"Heterocyclic ring", as opposed to "heteroaryl group"
and "non-aromatic heterocylic ring", is defined as imidazole, benzimidazole, pyridine, pyrimidine, thiazole, benzothiazole, thienyl, benzothienyl. It is noted further the terms "heterocyclic aromatic group" and "non-aromatic heterocyclic ring" are defined above and have different meanings from the term "heterocyclic ring".
Suitable substituents on an alkyl, aliphatic, aromatic, non-aromatic heterocyclic ring or benzyl group include, for example, -OH, halogen (-Br, -C1, -I and -F) -O(aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group), -CN, -N~~, -COOH, -NHZ, -NH(aliphatic group, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group), -N(aliphatic group, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group ), -COO(aliphatic group, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group), -CONHz, -CONH(aliphatic, substituted aliphatic group, benzyl, substituted benzyl, aromatic or substituted aromatic group)), -SH, -S(aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group) and -NH-C(=NH)-NH2. A substituted non-aromatic heterocyclic ring, benzylic group or aromatic group can also have an aliphatic or substituted aliphatic group as a substituent.
A substituted alkyl or aliphatic group can also have a non-aromatic heterocyclic ring, benzyl, substituted benzyl, aromatic or substituted aromatic group as a substituent. A
substituted non-aromatic heterocyclic ring can also have =O; =S, =NH or =N(aliphatic, aromatic or substituted aromatic group) as a substituent. A substituted aliphatic, substituted aromatic, substituted non-aromatic heterocyclic ring or substituted benzyl group can have more than one substituent.
In the structural formulas depicted herein, the single or double bond by which a chemical group or moiety is connected to the remainder of the molecule or compound is indicated by the following symbol:
,t n For example, the corresponding symbol in Structural Formula (V) or (VIII) indicates that the tricyclic ring system, which respresents Z in Structural Formula (I), is connected to the alkylene group in Structural Formula (I) by a single covalent bond between the alkylene group and the ring carbon in Ring C which is bonded to W.
A "subject" is preferably a mammal, such as a human, but can also be an animal in need of veterinary treatment, e.g., domestic animals (e. g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e. g., rats, mice, guinea pigs, and the like).
A "therapeutically effective amount" of a compound is a~ amount which results in the inhibition of one or more processes mediated by the binding of a chemokine to a receptor in a subject with a disease associated with aberrant leukocyte recruitment and/or activation. Examples of such processes include leukocyte migration, integrin activation, transient increases in the concentration of intracellular tree calcium [CaZ"]; and granule release of proinflammatory mediators. Alternatively, a "therapeutically effective amount" of a compound is a quantity sufficient to achieve a desired therapeutic and/or prophylactic effect, such as an amount which results in the prevention of or a decrease in the symptoms associated with a disease associated with aberrant leukocyte recruitment and/or activation.
The amount of compound administered to the individual will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
Typically, a therapeutically effective amount of the compound can range from about 0.1 mg per day to about 100 mg per day for an adult. Preferably, the dosage ranges from about 1 mg per day to about 100 mg per day. An antagonist of chemokine receptor function can also be administered in combination with one or more additional therapeutic agents, e.g. theophylline, G-adrenergic 5 bronchdilators, corticosteroids,'antihistamines, antiallergic agents, immunosuppressive agents (e. g., cyclosporin A, FK-506, prednisone, methylprednisolone) and the like.
The compound can be administered by any suitable 10 route, including, for example, orally in capsules, suspensions or tablets or by.parenteral administration.
Parenteral administration can include, for example, systemic administration, such as by intramuscular, intravenous, subcutaneous, or intraperitoneal injection.
15 The compound can also be administered orally (e. g., dietary), topically, by inhalation (e. g., intrabronchial, intranasal, oral inhalation or intranasal drops), or rectally, depending on the disease or condition to be treated. Oral or parenteral administration are preferred 20 modes of administration.
The compound can be administered to the individual ir.
conjunction with an acceptable pharmaceutical or physiological carrier as part of a pharmaceutical composition for treatment of HIV infection, inflammatory 25 disease, or the other diseases discussed above.
Formulation of a compound to be administered will vary according to the route of administration selected (e. g., solution, emulsion, capsule). Suitable carriers may contain inert ingredients which do not interact with the compound. Standard formulation techniques can be employed, such as those described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. Suitable carriers for parenteral administration include, for example, sterile water, physiological saline, bacteriostatic saline (saline containing about ;;.9% mg/ml benzyl alcohol), phosphate-buffered saline, Hank's solution, Ringer's-lactate and the like. Methods for encapsulating compositions (such as in a coating of hard gelatin cr cyclodextran) are known in the art ;Baker, et al., "Controlled Release of Biological Active Agents", John l0 Wiley and Sons, 1986).
The activity of compounds of the present invention can be assessed using suitable assays, such as receptor binding assays and chemotaxis assays. For example, as described in the Exemplification Section, small molecule antagonists of RANTES and MIP-la binding have been identified utilizing THP-1 cells which bind RANTES and chemotax in response to R.ANTES and MIP-la as a model for leukocyte chemotaxis.
Specifically, a high through-put receptor binding assay, which monitors lzsI-RANTES and lzsl_MIP-la binding to THP-1 cell membranes, was used to identify small molecule antagonists which block binding of RANTES and M1P-la.
Compounds of the present invention can also be identified by virtue of their ability to inhibit the activation steps triggered by binding of a chemokine to its receptor, such as chemotaxis, integrin activation and granule mediator release. They can also be identified by virtue of their ability to block RANTES and MIP-la mediated HL-60, T-cell, peripheral blood mononuclear cell, and eosinophil chemotactic response.
The compounds disclosed herein can be prepared accordingly to the schemes shown in Figures 1-3. The schemes are described in greater detail below.
Figure 1 is a schematic showing the preparation o~ the compounds represented by Structural Formula (I).
L', LZ and L' in Figure 1 are suitable leaving groups such as halogen; o-toluene sulfonate, mesylate, alkoxy and phenoxy. The other symbols are as defined above.
The reduction. reaction in Step 1 of Figure 1 is performed with a reducing agent such as or sodium borohydride or lithium aluminum hydride (LAH) in an inert solvent such as methanol or tetrahydrofuran (THF. The reaction is carried out at temperatures ranging from 0°C up to the reflux temperature and for 5 minutes to 72 h.
Compounds represented by formula II in Figure 1 can be prepared by procedures disclosed in JP 61/152673, U.S.
Patent 5089496, WO 89/10369, WO 92/20681 and WO 93/02081, the entire teachings of which are incorporated herein by reference.
A chlorination reaction in step 2 of Figure 1 can be performed with reagents such as thionyl chloride. The reaction can be carried out in an inert solvent such as methylene chloride at 0°C up to the reflux temperature for 5 minutes to 72 h. The hydroxy group can be also converted to other leaving groups by methods familiar to those skilled in the art.
The cyanatior. reaction in step 3 of Figure 1 can be carried out using reagents such as copper cyanide, silver cyanide or sodium cyanide in an inert solvent such as benzene or toluene. Reacton temperatures range from 0°C up to the reflux temperature for 5 minutes to 72 h. Compounds WO 99/37617 ~g PCT/US99/01265 represented by Formula V in Figure 1 can also be prepared by the procedures described in J. Med. Chem. 1994, 37, 804-810 and U.S. Patent 5672611, the entire teachings c which are incorporated herein by reference.
The alkylation reactions in steps 4 and 5 of Figure 1 can be carried out in a solvent such as acetone, methyl ethyl ketone, ethyl acetate, toluene, tetrahydrofuran (THF) or dimethylformamide (DMF) in the presence of a base such as potassium carbonate or sodium hydride and a catalyst IO such as an alkali metal iodide (when necessary}. The reaction temperature can range from room temperature up to the reflux temperature and for 5 minutes to 72 h.
The product of the synthetic scheme shown in Figure 1 can be decyanated using a reducing agent such as lithium aluminum hydride (LAH) in an inert solvent such as ether or tetrahydrofuran (THF) at 0°C up to the reflux temperature for the solvent used for 5 minutes to 72 h.
Figure 2 is a schematic showing the preparation of the compounds represented by Stuctural Formula (I) and II), wherein Z is represented by Structural Formulas (IV) and wherein Ring A in Z is substituted with - (CHz) t-COOH, - (CHZ) ~-COORZ° or - (CHZ) t-C (O) -NRzlR~2 .
In Figure 2, the hydrolysis reaction may be carried out in a mixture of aqueous alkali metal hydroxide solution and a solvent such as methanol, ethanol, tetrahydrofuran (THF) or dioxane at room temperature up to the reflux temperature for the solvent used~for 5 minutes to 72 h.
The acylation reaction can be carried out using dicyclohexylcarbodiimide (DCC) or (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (DEC) in a solvent such as tetrahydrofuran (THF), dimetrylformamide (DMF) or methylene chloride in the presence of a base such as pyridine or triethylamine (when necessary) at temperatures of 0 to 100°C for 5 minutes Lo 72 h.
Compounds represented by Structural Formulas (I) and (II), wherein Z is represented by Structural Formulas (XVI) , X is -CO-N(R~) - and R° is - (CHZ) S-COOH, - (CHz) S-COOR~°
or - (CHZ) S-C (O) -NR"R'2 can be prepared by suitable modification of the scheme shown in Figure 1. One modification utilizes the starting material shown in Figure 1, wherein X is -CO-NH-. The amide is then alkylated with L3- (CHZ) e-COOR'° using the alkylation procedures described above. L' is a suitable leaving group. The remainder of the synthesis is as described in Figures 1 and 2.
Figure 3 is a schematic showing the preparation of the compounds represented by Structural Formula (I) and (II), wherein Z is represented by Structural Formulas (VIII) and (XIII-(XVI) and wherein V is Wa.
The reduction of the cyano group to an amine in Figure 3 can be carried out using metal hydrides or by catalytic reduction processes. Suitable reducing agents include lithium aluminum hydride (LAH), diisobutyl aluminum hydride (DIBAL-H), borane-methyl sulfide complex or sodium borohydride. The reduction can be carried out in an inert solvent such as ether, tetrahydrofuran (THF), methylene chloride or methanol at -78°C up to the reflux temperature for 5 minutes to 72 h. It is also possible to isolate the corresponding imine intermediate, which can be converted to the amine using similar reduction processes.
Although Figures 1-3 show the preparation of compounds in which Rings A and B are phenyl rings, analogous compounds with heteroaryl groups for Rings A and B can be WO 99/37617 3o PCT/US99/O1Z65 prepared by using the starting materials with heteroaryl groups in the corresponding positions, which can be prepared according to methods disclosed in JP 6i/152673, U.S. Patent 5089496, WO 89/10369, WC 92/20681 and WO
93/02081.
The invention is illustrated by the following examples which are not intended to be limiting in any way.
EXEMPLIFICATION
Example 1 - Preparation of 4-(4-Chlorophenyl)1-[3-(5-cyano-5H-dibenzo[a,d]cycloheptene-5-yl)propyl]piperidin-4-of To a solution of 5H-dibenzo(a,d]cycloheptene-5-carbonitrile (described in J. Med Chem. 1994, 37, 804-810)(SOOmg) in DMF (lOml) were added 60% sodium hydride (110mg) and 1-bromo-3- chloropropane (0.30m1) and the mixture was stirred at room temperature for 1 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate.
The solvent was distilled off under reduced pressure to give 5-(3-chloropropy~-5H-dibenzo[a,d]cycloheptene-5-carbonitrile. Without purification, to a solution obtained chloride in DMF (lOml) were added 4-(4-chlorophenyl)-4- hydroxypiperidine (650mg), potassium carbonate (950mg), and potassium iodide (50mg) and the mixture was stirred at 70°C for 24 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:1) to give the titled compound (700mg) . 'H-NMR (CDC1,) d: l.z~-1.j4 ~~ri,m~ , 1.60-1.80(3H,m), 1.93-1.99(2H,m), 2.16-2.28(6H,m), 2 . 56-2.60 (2H,m) , 6.98 (2H, s) , 7.25-7.47 ClOH,m) , 8.00-8.03 (2H,m) . MS m/z: 469 (M+1) Example 2 - Preparation of 4-(4-Chlorophenyl)-1-[3-(5-cyano-10,11-dihydro-5H-dibenzo[a;d]cycloheptene-5-yl)propyl]piperidin-4-of Following the procedure of example l, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-carbonitrile, the titled compound was prepared. 1H-NMR (CDC1,) 8:
1.43-1.49(2H,m), 1.61-1.66(2H,m), 1.93-2.02(3H,m), 2.24-2.32(4H,m), 2.48-2.62(4H,m), 2.96-3.06(2H,m), 3.35-3.45 (2H,m) , 7.11-7.41 (lOH,m) , 7.93-7. 97 (2H,m) . MS
m/z: 471(M+1) Example 3 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenz[b,a]oxepin-11-yl)propyl]piperidin-4-0l Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 6,11-dihydrodibenz[b,e]oxepin-11-carbonitrile, the titled compound was prepared. 1H-NMR (CDC13) 8: 1.37-1.68(5H,m), 1.99-2.09(2H,m), 2.24-2.50(SH,m), 2.65-2.69(2H,m), 2.78-2.85(lH,m), 5.03(lH,d), 5.45(lH,d), 7.02-7.43(lOH,m), 7.82-7.86(lH,m), 7.95-8.00(lH,m). MS m/z: 473(M+1) Example 4 - Preparation of 1-[3-(11-Cyano-6,11-dihydrodibenz[b,e]oxepin-11-yl)propyl]-4-(4-fluorophenyl)piperidin-4-of Following the procedure of example 3, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-(4-fluorophenyl)- 4-hydroxypiperidine, the titled compound was prepared. -H-NMR (CDC1~) ~: 1.40-1.68(4H;m), 1.88-2.08(3H,m), 2.29-2.50(5H,m), 2.63-2.67(2H,m), 2 . 77-2 . 84 ( 1H, m) , 5 . 03 ( 1H, d) , 5 . 44 ( 1H, d) , 6 . 95-7 . 46 ( lOH, m) , 7.81-7.85(lH,m), 7.94-7.99(lH,m). MS m/z: 457(M+1) Example 5 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-2-fluorodibenz[b,e]oxepin-11-yl)propyl]piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 6,11-dihydro-2-fluorodibenz[b,e]oxepin-11-carbonitrile, the titled compound was prepared. 1H-NMR (CDC13) 8:
1.37-1.69(SH,m). 1.98-2.09(2H,m), 2.25-2.48(SH,m), 2.65-2.70(2H,m), 2.78-2.87(lH,m), 5.01(lH,d), 5.42(lH,d), 6.99-7.11(3H,m), 7.25-7.43(6H,m), 7.54-7.59(lH,m), 7.92-7.95 (lH,m) . MS m/z: 491 (M+1) Example 6 - Preparation of 1-[3-(2-Bromo-11-cyano-6,11-dihydrodibenz[b,e]oxepin-11-yl)propyl]-4-(4-chlorophenyl)piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 2-bromo-6,11-dihydrodibenz[b,e]oxepin-11-carbonitrile, the titled compound was prepared. 1H-NMR tCDCl3) b:
1.37-1.69(SH,m), 1.97-2.09(2H,m), 2.24-2.48(SH,m), 2.66-2.85 (3H,m) , 5.00 (lH,d) , 5.43 .(lH,d) , 6.97-7.02 (2H,m) , 7.24-7.46 (7H,m) , 7.91-7.95 (2:-i,m) .
MS m/z: 551, 553(M+1) Example 7 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-2-methyldibenz[b,e]oxepin-11-yl)propyl]piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with IO 6,11-dihydro-2-methyldibenz[b,e]oxepin-11-carbonitrile, the titled compound was prepared. 'H-NMR (CDC13) b:
1 .40-1.70 (SH,m) , 1.98-2.09 (2H,m) , 2.25-2.52 (8H,m) , 2.68-2.73(2H,m), 2.81-2.90(lH,m), 5.00(lH,d), 5.44(lH,d), 6.98-7.43 (9H,m) , 7.63 (lH,d) , 7.94-7.98 (lH,m) . MS m/z:
487(M+1) Example 8 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-3,4-dichloro-6,11-dihydro-dibenz[b,e]oxepin-11-yl)propyl]piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 3,4-dichloro-6,11-dihydrodibenz[b,e]oxepin-11-carbonitrile, the titled compound was prepared. 1H-NMR (CDC13) 8:
1.40-1.71(SH,m), 2.00-2.10(2H,m), 2.28-2.50(SH,m), 2.65-2.85(3H,m), 5.04(lH,d), 5.46(lH,d), 6.99-7.03(lH,m), 7.26-7.44 (7H,m) , 7.91-7.95 (2H,m) . MS m/z: 541 (M+1) Example 9 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-2,3-methylenedioxydibenz[b,e]oxepin-11-yl)propyl]piperidin-4-of Following the procedure of example 1, b~~ replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 6,11-dihydro-2,3- methylenedioxydibenz[b,e]oxepin-11-carbonitrile, the titled compound was prepared. 'H-NMR
(CDC13) b: 1.60-1.90 (SH,m) , 2.30-2.50 (2H,m) , 2.80-3.30 (8H,m) , 5.05 (lH,d) , 5.45 (lH,d) , 6.02 (2H,brd) , 6.68(lH,s), 6.97-7.01(lH,m), 7.26-7.43(7H,m), 7.83-7. 87 (2H,m) . MS m/z: 517 (M+1) Example 10 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 6,11-dihydrodibenzo(b,e]thiepin-11-carbonitrile, the titled compound was prepared. 'H-NMR (CDC13) 8: 1.63-1.76(SH,m), 2.03-2.16 (2H,m) , 2.37-2.52 (4H,m) , 2.72-2.85 (3H,m) , 3.03-3.10 (lH,m) , 4.10 (iH,d) , 4.54 (lH,d) , 7.13-7.44 (lOH,m) , 7.81-7.87(2H,m). MS m/z: 489(M+1) Example 11 - Preparation of 1-(3-(11-Cyano-6,11-dihydrodibenzo(b,e]thiepin-11-yl)propyl]-4-phenylpiperidin-4-0l Following the procedure of example 10, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 4-hydroxy-4-phenylpiperidine, the titled compound was prepared.
1H-NMR (CDC1;) 8: 1.63-1.77 (SH,m) , 2.02-2.16 (2H,m) , 2.37-2.52(4H,m), 2.72-2.85(3H,m), 3.03-3.10(lH,m), 4 . 10 (1H, d) , 4 . 55 (1H, d) , 7 . 13-7 . 52 (lOH, m) , 7 . 81-7 . 80 (2H, m) .
MS m/z: 455(M+1) 5 Example 12 - Preparation of 4-(4-Bromophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of Following the procedure of example 10, but replacing 4-(4-chlorophenyl)-4-hydroxypiperidine with 10 4-(4-bromophenyl)-4- hydroxypiperidine, the titled compound was prepared. 'H-NMR (CDC13) b: 1.64-1.82 (SH,m) , 2.02-2.12 (2H,m) , 2.32-2.48 (4H,m) , 2.69-2.85 (3H,m) , 2.99-3.09(lH,m), 4.07(lH,d), 4.50(lH,d), 7.11-7.46(lOH,m), 7.79-7.86(2H,m). MS m/z: 533, 535(M+1) 15 Example 13 - Preparation of 1-(3-(2-Bromo-11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]-4-(4-chlorophenyl)piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 20 2-bromo-6,11-dihydrodibenzo[b,e]thiepin-11-carbonitrile, the titled compound was prepared.lH-NMR (CDC1,) 8:
1. 63-1.78 (SH,m) , 2 .03-2.14 (2H,m) , 2.35-2 .52 (4H,m) , 2.72-2.80(3H,m), 3.00-3.10(lH,m), 4.15(lH,brd), 4.50(lH,d), 7.07-7.45(lOH,m), 7.73-7.81(lH,m), 7.95(lH,d). MS m/z: 567, 25 569 (M+1) WO 99!37617 36 PCT/US99/O1Z65 Example 14, 15 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-5-oxodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 6,11-dihydro-5-oxcdibenzo[b,e]thiepin-11-carbonitrile, the titled compound :~~as prepared. The diastereomers were separated by silica gel chromatography. isomer 1 'H-NMR
(CDC13) 8: 1.20-1.35(lH,m), 1.63-1.69(4H,m), 2.04-2.84(lOH,m), 4.21(lH,d), 4.31(lH,d), 7.18-7.65(9H,m), 8.03-8. 13 (3H,m) . MS m/z: 505 (M+1) isomer 2 1H-NMR (CDC13) d:
1.25-1.38(lH,m), 1.65-2.15(6H,m), 2.28-2.82(BH,m), 4.65(lH,d), 4.82(lH,d), 7.27-7.56(9H,m), 7.92-8.00(3H,m).
MS m/z: 505 (M+1) Example 16 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-cyano-6,11-dihydro-5,5-dioxodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of Following the procedure of example 1, but replacing 5H-dibenzo[a,d]cycloheptene-5-carbonitrile with 6,11-dihydro-5,5-dioxodibenzo[b,e]thiepin-11-carbon~trile, the titled compound was prepared. 'H-NMR (CDC13) ~:
1.40-2.72(l4H,m), 3.08-3.22(lH,m), 4.58(lH,d), 5.58(lH,d), 7.29-7.58(9H,m), 7.99-8.13(3H,m). MS m/z: 521(M+1) WO 99/37617 3,~ PCTlUS99/O1Z65 Example 17 - Preparation of 4-(4-Chlorophenyl)-1-[3-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of To a solution of 4-(4-chlorophenyl)-1-[3-(11-cyano-6,11- dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of (430mg) in THF lOml) was added 1M
lithium aluminum hydride THF solution (1.5m1) and the mixture was heated to reflux for 3 hours. The reaction mixture was cooled with ice, water (0.06m1), then 15%
aqueous sodium hydroxide (0.06m1), then water (0.18m1) were added carefully. The granular salt was filtered off and the filtrate was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:1) to give the titled compound (280mg) . 1H-NMR (CDC13) b: 1.55-1.80 (4H,m) , 2.03-2.16(2H,m), 2.25-2.52(6H,m), 2.72-2.80(2H,m), 3.90(lH,brs), 4.48(lH,brt), 4.68(lH,brs), 6.96-7.45(l2H,m).
MS m/z: 464 (M+1) Example 18 - Preparation of 4-(4-Chlorophenyl)-1-[3-(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-yl)propyl]piperidin-4-0l Following the procedure of example 17, but replacing 4-(4-chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of with 4-(4-chlorophenyl)-1-[3-(5-cyano-10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-yl)propyl]piperidin-4-ol, the titled compound was prepared. 'H-NMR (CDC1;) b:
1.40-1.58(2H,m), 1.62-1.71(2H,m), 1.98-2.20(4H,m), 2.30-2.42 (4H,m) , 2.67-2.78 (2H,m) , 2.95-3.08 (2H,m) , WO 99/37617 3g PCT/US99/01165 3 .30-3 .44 (2H,m) , 4.01 (1H, t) , 7.10-7.46 (l2H,m) . MS m/z:
446 (M+1) Example 19 - Preparation of 4-(4-Chlorophenyl)-1-[3-(6,11-dihydrodibenz[b,e]oxepin-11-yl)propyl]piperidin-4-of Following the procedure of example 17, but replacing 4-(~-crlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,e]t~iepin-11-yl)propyl]piperidin-4-of with 4-(4-chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenz[b,e]ox epin- 11-yl)propyl]piperidin-4-ol,. the titled compound was prepared. 1H-NMR {CDC13) 8: 1.36-1.49 (2H,m) , 1.58-1.67(2H,m), 1.95-2.33(8H,m), 2.63-2.68(2H,m), 3 .74 (1H, t) , 4.95 (1H, d) , 5.48 (lH,d) , 6.95-7.39 (l2H,m) . MS
m/z: 448{M+1) Example 20 - Preparation of 4-(4-Chlorophenyl)-1-[3-(6,11-dihydro-11-iminodibenzo[b,e]thiepin-11-yl)propyl]
piperidin-4-of To a solution of 4-(4-chlorophenyl)-1-[3-(11-cyano-6,11-dihydrodibenzo[b,elthiepin-11-yl)propyl]piperidin-4-of (1.92g) in dichloromethane (30m1) at -78°C was added 1M
diisobutyl aluminum hydride dichloromethane solution (lOml). The reaction mixture was warmed to room temperature, and stirred for 30 minutes. Water and dichloromethane were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate.
The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate to give the titled compound (1.16g).
1H-NMR (CDC13) 8: 1.65-1.80 (SH,m) , 2.02-2.18 (2H,m) , 2.45-2.60 (6H,m) , 2.78-2.86 (2H,m) , 3.82 {lH,d) , 4.25 (lH,d) , 7.05-7.45(l2H,m), 8.28(lH,brs). MS m/z: 491(M+1) Example 21 - Preparation of 4-(4-Chlorophenyl)-1-[3-(11-aminomethyl-6,11-dihydrodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of To a solution of 4-(4-chlorophenyl)-1-[3-(6,11-dihydro-11-iminodibenzo[b,e]thiepin-11-yl)propyl]piperidin-4-of (600mg) in methanol (15m1) was sodium borohydride (220mg), and the mixture was stirred at room temperature for 10 hours. The solvent was distilled off under reduced pressure. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced to give the titled compound (600mg). MS
m/z:493(M+1) Example 22 - Preparation of Phenyl N- [2- (3- [4- (4-chlorophenyl)- 4-hydroxypiperidino]propyl]-2-(6,11-dihydrodibenzo[b,e]thiepin- 11-yl)ethyl] carbamate To a solution of 4-(4-chlorophenyl)-I-[3-(11-aminomethyl-6,1i-dihydrodibenzo[b,e]thiepin-11-yl)propyl] piperidin-4-of (610mg) in THF (20m1) was triethylamine (0.2m1) and phenyl chlorocarbonate (0.16m1) at 0°C, and the mixture was stirred for 1 hours. Water and ethyl acetate were added to the reacticn mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate.
$O
The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate to give the titled compound (400mg).
1H-NMR (CDC13) b: 1.40-2.90 (lSH,m) , 4.05-4. i2 (2H,m) , 4.38(lH,d), 4.50-4.60(lH,m), S.98(lH,brs), 6.96-7.54(l7H,m). MS m/z: 613(M+1) Example 23 - Preparation of 1-[2-[3-[4-(4-chiorophenyl)-4-hydroxypiperidino]propyl]-2-(6,11-dihydrodibenzo[b,e]thiepin-11-yl)ethyl]-3-(hydroxypropyl)urea To a solution phenyl N- [2- [3- [4- (4-chlorophenyl) -4-hydroxypiperidino]propyl]-2-(6,1I-dihydrodibenzo[b,e]thiepin-11-yl)ethyl] carbamate (300mg) in DMF (lOml) were added 3-amino-1-propanol (70mg), potassium carbonate (130mg) and the mixture was stirred at room temperature for 16 hours. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-methanol (9:1) to give the titled compound (200mg).
1H-NMR (CDC1;) d: 1.40-1.70 (6H,m) , 2.01-2. 08 (2H,m),, 2 . 30-2 . 63 (8H, m) , 3 . 12 (2H, q) , 3 .42 (2H, t) , 4 . 00-4 . 12 (2H, m) , 4.22-4.28(2H,m), 4.82(lH,brt), 4.99(lH,brs), 6.98-7.45(l2H,m).MS m/z: 594(M+1) Example 24 - Preparation of 4-(4-Chlorophenyl)-1-[3-(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-yl)-3-propioyl]piperidin-4-of To a solution 10,11-dihydro-5H-dibenzo[a, d]
cycloheptene-5-carbonitrile (500mg) in THF (5m1) was added 1.6M n-butyl lithium hexane solution (1:8m1) at 0°C. The mixture was warmed to room temperature, and stirred for 20 minutes. Tc the reaction mixture cooled to 0°C was added ethyl 3-(4-(4-chlorophenyl)-4- hydroxypiperidine-1-yl)propionate (310mg) dropwise as THF solution (2m1), and the mixture was warmed to room temperature, and stirred for 30 minutes. Water and ethyl acetate were added to the reaction mixture, the organic layer was separated and washed with saturated aqueous sodium chloride, and dried over magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was purified by silica gel chromatography eluting with ethyl acetate-hexane (1:1) to give the titled compound (380mg) . 1H-NMR (CDC13) 8:
1.57-1.62 (2H,m) , 1.91-2.01 (3H,m) , 2.27-2.84 (lOH,m) , 3.30-3.44(2H,m), 4.65(lH,s), 7.10-7.38(l2H,m).
MS m/z: 460{M+1) Examples 28 - 59 can be prepared by methods set forth in the schemes in Figure 1-3 and the procedures described above.
Example 60 Membrane Preparations for Chemokine Binding and Binding Assays Membranes were prepared from THP-1 cells (ATCC #TIB2G2).
Cells were harvested by centrifugation, washed twice with PBS (phosphate-buffered saline), and the cell pellets were frozen at -70 to -85°C. The frozen pellet was thawed in ice-cold l~,rsis buffer consisting of 5 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethane-sulfonic acid) pH 7.5, 2 mM EDTA (ethylenediaminetetraacetic acid), 5 ~cg/ml each aprotinin, leupeptin, and chymostatin (protease inhibitors), and 100 ~cg/ml PMSF (phenyl methane sulfonyl fluoride - also a protease inhibitor), at a concentration of 1 to 5 x 10' cells/ml. This procedure results in cell lysis. The suspension was mixed well to resuspend all of the frozen cell pellet. Nuclei and cell debris were removed by centrifugation of 400 x g for 10 minutes at 4°C.
The supernatant was transferred to a fresh tube and the membrane fragments were collected by centrifugation at 25,000 x g for 30 minutes at 4°C. The supernatant was aspirated and the pellet was resuspended in freezing buffer consisting of 10 mM HEPES pH 7.5, 300 mM sucrose, l~g/ml each aprotinin, leupeptin, and chymostatin, and 10 ~cg/ml PMSF (approximately 0.1 ml per each I08 cells). All clumps were resolved using a minihomogenizer, and the total protein concentration was determined using a protein assay kit (Bio-Rad, Hercules, CA, cat #500-0002). The membrane solution was then aliauoted and frozen at -70 to -85°C
until needed.
~3 Binding Assays utilized the membranes described above.
Membrane protein (2 to 20 ~.g total membrane protein) was incubated with 0.1 to 0.2 nM izSl-labeled RANTES or MIF-icx with or without unlabeled competitor (RANTES or MIP-la) or various concentrations of compounds. The binding reactions were performed in 60 to laa ul of a binding buffer consisting of 10 mM uEPES pH 7.2, 1 mM CaClz, 5 mM MgClz, and 0.5% BSA (bovine serum albumin), for 60 min at room temperature. The binding reactions were terminated by harvesting the membranes by rapid filtration through glass fiber filters (GF/B or GF/C, Packard) which were presoaked in 0.3% polyethyleneimine. The filters were rinsed with approximately 600 ~.1 of binding buffer containing 0.5 M
NaCl, dried, and the amount of bound radioactivity was determined by scintillation counting in a Topcount beta-plate counter.
The activities of test compounds are reported in the Table below as ICSO values or the inhibitor concentration required for 50% inhibition of specific binding in receptor G
binding assays using 12~'I-RANTES or lzsMIP-la as ligand and THP- .1 cell membranes. Specific binding is defined as the total binding minus the non-specific binding; non-specific binding is the amount of cpm still detected in the presence of excess unlabeled Rantes or l2sMIP-la.
Table BIOLOGICAL DATA
Example ICSo (ACM) 1 0.088 2 0.052 3 0.11 4 0.39 5 0.19 6 0.30 7 0.38 10 0.097 12 0.099 13 0.38 14 0.28 15 0.61 16 0.079 17 0.070 18 0.055 19 0.059 22 0.69 23 2.2 24 0.16 25 0.13 26 0.61 27 0.48 4~
Those skilled in the art will be able to recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (43)
1. A method of treating a disease associated with aberrant leukocyte recruitment and/or activation comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by the following structural formula:
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond, -O- or -CO-;
n is an integer from one to five;
X is a covalent bond or -CO-;
M is >NR2 or >CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
Z is represented by the following structural formula:
wherein Ring C is a substituted or unsubstituted C6 to C8 non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring and is bonded to the remainder of the molecule by a single covalent bond between Y and a carbon atom in Ring C;
and Ring A and Ring B are each, independently, substituted or unsubstituted.
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond, -O- or -CO-;
n is an integer from one to five;
X is a covalent bond or -CO-;
M is >NR2 or >CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
Z is represented by the following structural formula:
wherein Ring C is a substituted or unsubstituted C6 to C8 non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring and is bonded to the remainder of the molecule by a single covalent bond between Y and a carbon atom in Ring C;
and Ring A and Ring B are each, independently, substituted or unsubstituted.
2. The method of Claim 1 wherein X is a covalent bond and Y is a single covalent bond between a carbon atom in Ring C and the (CH2)n moiety.
3. The method of Claim 2 wherein Z is represented by a structural formula selected from:
wherein:
X1 is -S-, -CH2- or -CH2S-; and W is -H or an electron withdrawing group.
wherein:
X1 is -S-, -CH2- or -CH2S-; and W is -H or an electron withdrawing group.
4. The method of Claim 3 wherein Z is represented by the following structural formula:
5. The method of Claim 4 wherein W is -H or -CN.
6. The method of Claim 5 wherein R1 is -OH.
7. The method of Claim 6 wherein M is >C(OH)R2 and n is three.
8. The method of Claim 7 wherein R2 is a substituted or unsubstituted aromatic group.
9. The method of Claim 1 wherein X is a covalent bond and Y is -CO-.
10. The method of Claim 2 wherein Z is represented by a structural formula selected from:
wherein:
X1 is -S-, -CH2- or -CH2S-;
W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl;
Ring A is substituted with R8 and R9;
R8 and R9 are each, independently, -H, a halogen, alkoxy or alkyl, or R8 and R9, taken together with Ring A, form a naphthyl group;
n is an integer from 2-5;
M is >N(alkanoyl), >N(aroyl), >N(aralkoyl), >N(alkyl), >N(aralkyl), >N(cycloalkyl), >C(OH) (aryl) or >CH(heteroaryl).
wherein:
X1 is -S-, -CH2- or -CH2S-;
W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl;
Ring A is substituted with R8 and R9;
R8 and R9 are each, independently, -H, a halogen, alkoxy or alkyl, or R8 and R9, taken together with Ring A, form a naphthyl group;
n is an integer from 2-5;
M is >N(alkanoyl), >N(aroyl), >N(aralkoyl), >N(alkyl), >N(aralkyl), >N(cycloalkyl), >C(OH) (aryl) or >CH(heteroaryl).
11. The method of Claim 1 wherein the compound is represented by a structural formula selected from:
12. The method of Claim 2 wherein Z is represented by a structural formula selected from:
wherein Rings A, B and C are each, independently, substituted or unsubstituted.
wherein Rings A, B and C are each, independently, substituted or unsubstituted.
13. The method of Claim 1 wherein Z is:
wherein V is -H, an electron withdrawing group, -CH2-NR11R12, -CH2-OR11, -CH2-NH-CO-NR11R12 or -CH2-O-CO-NR11R12;
R11 and R12 are each independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or R11 and R12 taken together with the nitrogen atom to which they are bonded form a non-aromatic heterocyclic ring; and Ring A and Ring B are independently substituted or unsubstituted.
wherein V is -H, an electron withdrawing group, -CH2-NR11R12, -CH2-OR11, -CH2-NH-CO-NR11R12 or -CH2-O-CO-NR11R12;
R11 and R12 are each independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or R11 and R12 taken together with the nitrogen atom to which they are bonded form a non-aromatic heterocyclic ring; and Ring A and Ring B are independently substituted or unsubstituted.
14. A method of treating a disease associated with aberrant leukocyte recruitment and/or activation comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by the following structural formula:
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond, -O- or -CO-;
n is an integer from one to five;
X is a covalent bond or -CO-;
M is >NR2 or >CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
Z is represented by the following structural formula:
wherein Ring A is a carbocyclic aromatic ring or a heteroaromatic ring, Ring B is a heteroaromatic ring and each ring in Z is independently substituted or unsubstituted;
W b is -H, -CN, -CH2-NR11R12, -CH2-OR11, -CH2-NH-CO-NR11R12 or -CH2-O-CO-NR11R12 R11 and R12 are each independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or R11 and R12 taken together with the nitrogen atom to which they are bonded form a non-aromatic heterocyclic ring.
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond, -O- or -CO-;
n is an integer from one to five;
X is a covalent bond or -CO-;
M is >NR2 or >CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
Z is represented by the following structural formula:
wherein Ring A is a carbocyclic aromatic ring or a heteroaromatic ring, Ring B is a heteroaromatic ring and each ring in Z is independently substituted or unsubstituted;
W b is -H, -CN, -CH2-NR11R12, -CH2-OR11, -CH2-NH-CO-NR11R12 or -CH2-O-CO-NR11R12 R11 and R12 are each independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or R11 and R12 taken together with the nitrogen atom to which they are bonded form a non-aromatic heterocyclic ring.
15. A compound represented by the following structural formula:
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond or -C(O)-;
X is a covalent bond;
M is > NR2 or > CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
n is an integer from one to five;
Z is represented by the following structural formula:
W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl; and Ring A is substituted with R8 and R9, wherein R8 and R9 are each, independently, a halogen, alkoxy or alkyl, or R8 and R9, taken together with Ring A, form a naphthyl group.
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond or -C(O)-;
X is a covalent bond;
M is > NR2 or > CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
n is an integer from one to five;
Z is represented by the following structural formula:
W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl; and Ring A is substituted with R8 and R9, wherein R8 and R9 are each, independently, a halogen, alkoxy or alkyl, or R8 and R9, taken together with Ring A, form a naphthyl group.
16. The compound of Claim 15 wherein Y is a covalent bond.
17. The compound of Claim 16 wherein M is >N(alkanoyl), >N(aroyl), >N(aralkoyl), >N(alkyl), >N(aralkyl), >N(cycloalkyl), >C(OH)(aryl) or >CH(heteroaryl).
18. A compound represented by the following structural formula:
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond or -C(O)-;
n is an integer from one to five;
X is a covalent bond;
M is >NR2 or >CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic-group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
Z is represented by the following structural formula:
wherein Ring A is a carbocyclic aromatic ring or a heteroaromatic ring, Ring B is a heteroaromatic ring and each ring in Z is independently substituted or unsubstituted;
W b is -H, -CN, -CH2-NR11R12, -CH2-OR11, -CH2-NH-CO-NR11R12 or -CH2-O-CO-NR11R12;
R11 and R12 are each independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or R11 and R12 taken together with the nitrogen atom to which they are bonded form a non-aromatic heterocyclic ring.
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond or -C(O)-;
n is an integer from one to five;
X is a covalent bond;
M is >NR2 or >CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic-group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
Z is represented by the following structural formula:
wherein Ring A is a carbocyclic aromatic ring or a heteroaromatic ring, Ring B is a heteroaromatic ring and each ring in Z is independently substituted or unsubstituted;
W b is -H, -CN, -CH2-NR11R12, -CH2-OR11, -CH2-NH-CO-NR11R12 or -CH2-O-CO-NR11R12;
R11 and R12 are each independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or R11 and R12 taken together with the nitrogen atom to which they are bonded form a non-aromatic heterocyclic ring.
19. The compound of Claim 18 wherein Y is a covalent bond.
20. Use of a compound for the manufacture of a medicament for the treatment or prevention of a disease in a subject, said disease being associated with aberrant leukocyte recruitment and/or activation, and said compound being represented by the following structural formula:
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond, -O- or -CO-;
n is an integer from one to five;
X is a covalent bond or -CO-;
M is >NR2 or >CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
Z is represented by the following structural formula:
wherein Ring A is a carbocylic aromatic ring or a heteroaromatic ring, Ring B is a heteroaromatic ring and each ring in Z is independently substituted or unsubstituted;
W b is -H, -CN, -CH2-NR11R12, -CH2-OR11, -CH2-NH-CO-NR11R12 or -CH2-O-CO-NR11R12;
R11 and R12 are each independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O- (aliphatic group) , -NHC (O) -O- (aromatic group) or R11 and R12 taken together with the nitrogen atom to which they are bonded form a non-aromatic heterocyclic ring.
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond, -O- or -CO-;
n is an integer from one to five;
X is a covalent bond or -CO-;
M is >NR2 or >CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
Z is represented by the following structural formula:
wherein Ring A is a carbocylic aromatic ring or a heteroaromatic ring, Ring B is a heteroaromatic ring and each ring in Z is independently substituted or unsubstituted;
W b is -H, -CN, -CH2-NR11R12, -CH2-OR11, -CH2-NH-CO-NR11R12 or -CH2-O-CO-NR11R12;
R11 and R12 are each independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O- (aliphatic group) , -NHC (O) -O- (aromatic group) or R11 and R12 taken together with the nitrogen atom to which they are bonded form a non-aromatic heterocyclic ring.
21. The use of Claim 20 wherein X and Y are each a covalent bond.
22. A compound represented by the following structural formula:
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond or -C(O)-;
X is a covalent bond;
M is >NR2 or >CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
n is an integer from one to five;
Z is wherein V is -H, an electron withdrawing group, -CH2-NR11R12, -CH2-OR11, -CH2-NH-CO-NR11R12 or -CH2-O-CO-NR11R12;
R11 and R12 are each independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or R11 and R12 taken together with the nitrogen atom to which they are bonded form a non-aromatic heterocyclic ring; and Ring A and Ring B are independently substituted or unsubstituted.
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond or -C(O)-;
X is a covalent bond;
M is >NR2 or >CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
n is an integer from one to five;
Z is wherein V is -H, an electron withdrawing group, -CH2-NR11R12, -CH2-OR11, -CH2-NH-CO-NR11R12 or -CH2-O-CO-NR11R12;
R11 and R12 are each independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O-(aromatic group) or R11 and R12 taken together with the nitrogen atom to which they are bonded form a non-aromatic heterocyclic ring; and Ring A and Ring B are independently substituted or unsubstituted.
23. The compound of Claim 22 wherein Y is a covalent bond.
24. The compound of Claim 23 wherein W is -CN.
25. The compound of Claim 24 wherein R1 is -OH.
26. The compound of Claim 25 wherein M is > C(OH)R2 and n is three.
27. The compound of Claim 26 wherein R2 is a substituted or unsubstituted aromatic group.
28. The compound of Claim 22 wherein Ring A is substituted with R8 and R9, wherein R8 and R9 are independently a halogen, alkoxy or alkyl, or, taken together with Ring A, form a naphthyl group.
29. The compound of Claim 28 wherein M is > N(alkanoyl) , > N (aroyl) , > N(aralkoyl), > N(alkyl), > N(aralkyl) , > N(cycloalkyl) , > C(OH) (aryl) or > CH(heteroaryl).
30. Use of a compound for the manufacture of a medicament for the treatment or prevention of a disease in a subject, said disease being associated with aberrant leukocyte recruitment and/or activation, and said compound being represented by the following structural formula:
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond, -O- or -C(O)-;
X is a covalent bond or -C(O)-;
M is > NR2 or > CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
n is an integer from one to five;
Z is wherein V is -H, an electron withdrawing group, -CH2-NR11R12, -CH2-OR11, -CH2-NH-CO-NR11R12 or R11 and R12 are each independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC (O) -O- (aliphatic group), -NHC (O) -O- (aromatic group) or R11 and R12 taken together with the nitrogen atom to which they are bonded form a non-aromatic heterocyclic ring; and Ring A and Ring B are independently substituted or unsubstituted.
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond, -O- or -C(O)-;
X is a covalent bond or -C(O)-;
M is > NR2 or > CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
n is an integer from one to five;
Z is wherein V is -H, an electron withdrawing group, -CH2-NR11R12, -CH2-OR11, -CH2-NH-CO-NR11R12 or R11 and R12 are each independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -NHC (O) -O- (aliphatic group), -NHC (O) -O- (aromatic group) or R11 and R12 taken together with the nitrogen atom to which they are bonded form a non-aromatic heterocyclic ring; and Ring A and Ring B are independently substituted or unsubstituted.
31. The use of Claim 30 wherein X and Y are each a covalent bond.
32. Use of a compound for the manufacture of a medicament for the treatment or prevention of a disease in a subject, said disease being associated with aberrant leukocyte recruitment and/or activation, and said compound being represented by the following structural formula:
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond, -O- or -CO-;
n is an integer from one to five;
X is a covalent bond or -CO-;
M is >NR2 or >CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
Z is represented by the following structural formula:
wherein Ring C is a substituted or unsubstituted C6 to C8 non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring and is bonded to the remainder of the molecule by a single covalent bond between Y and a carbon atom in Ring C; and Ring A and Ring B are each, independently, substituted or unsubstituted.
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond, -O- or -CO-;
n is an integer from one to five;
X is a covalent bond or -CO-;
M is >NR2 or >CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
Z is represented by the following structural formula:
wherein Ring C is a substituted or unsubstituted C6 to C8 non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring and is bonded to the remainder of the molecule by a single covalent bond between Y and a carbon atom in Ring C; and Ring A and Ring B are each, independently, substituted or unsubstituted.
33. The use of Claim 32 wherein X is a covalent bond and Y is a single covalent bond between a carbon atom in Ring C and the (CH2)n moiety.
34. The use of Claim 33 wherein Z is represented by a structural formula selected from:
wherein:
X1 is -S- , -CH2- or -CH2S- ; and W is -H or an electron withdrawing group.
wherein:
X1 is -S- , -CH2- or -CH2S- ; and W is -H or an electron withdrawing group.
35. The use of Claim 32 wherein Z is represented by a structural formula selected from:
wherein:
X1 is -S-, -CH2- or -CH2S-;
W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl;
Ring A is substituted with R8 and R9;
R8 and R9 are each, independently, -H, a halogen, alkoxy or alkyl, or R8 and R9, taken together with Ring A, form a naphthyl group;
n is an integer from 2-5;
M is >N(alkanoyl), >N(aroyl), >N(aralkoyl), >N(alkyl), >N(aralkyl), >N (cycloalkyl), >C (OH) (aryl) or >CH (heteroaryl).
wherein:
X1 is -S-, -CH2- or -CH2S-;
W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl;
Ring A is substituted with R8 and R9;
R8 and R9 are each, independently, -H, a halogen, alkoxy or alkyl, or R8 and R9, taken together with Ring A, form a naphthyl group;
n is an integer from 2-5;
M is >N(alkanoyl), >N(aroyl), >N(aralkoyl), >N(alkyl), >N(aralkyl), >N (cycloalkyl), >C (OH) (aryl) or >CH (heteroaryl).
36. The use of Claim 32 wherein the compound is represented by a structural formula selected from:
37. The use of Claim 32 wherein Z is represented by a structural formula selected from:
wherein Rings A, B and C are each, independently, substituted or unsubstituted.
wherein Rings A, B and C are each, independently, substituted or unsubstituted.
38. Use of a compound for the manufacture of a medicament for the treatment or prevention of a disease associated with aberrant leukocyte recruitment and/or activation in a subject, said disease being selected from arthritis, psoriasis, multiple sclerosis, ulcerative colitis, Crohn's disease, allergy, asthma, AIDS associated encephalitis, AIDS related maculopapular skin eruption, AIDS related interstitial pneumonia, AIDS related enteropathy, AIDS related periportal hepatic inflammation and AIDS related glomerulo nephritis, and said compound being represented by the following structural formula:
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond, -O- or -CO-;
n is an integer from one to five;
X is a covalent bond or -CO-;
M is > NR2 or > CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
Z is represented by the following structural formula;
wherein Ring C is a substituted or unsubstituted C6 to C8 non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring and is bonded to the remainder of the molecule by a single covalent bond between Y and a carbon atom in Ring C; and Ring A and Ring B are each, independently, substituted or unsubstituted.
and physiologically acceptable salts thereof, wherein:
Y is a covalent bond, -O- or -CO-;
n is an integer from one to five;
X is a covalent bond or -CO-;
M is > NR2 or > CR1R2;
R1 is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);
R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;
Z is represented by the following structural formula;
wherein Ring C is a substituted or unsubstituted C6 to C8 non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring and is bonded to the remainder of the molecule by a single covalent bond between Y and a carbon atom in Ring C; and Ring A and Ring B are each, independently, substituted or unsubstituted.
39. The use of Claim 38 wherein X is a covalent bond and Y is a single covalent bond between a carbon atom in Ring C and the (CH2)n moiety.
40. The use of Claim 39 wherein Z is represented by a structural formula selected from:
wherein:
X1 is -S-, -CH2- or -CH2S-; and W is -H or an electron withdrawing group.
wherein:
X1 is -S-, -CH2- or -CH2S-; and W is -H or an electron withdrawing group.
41. The use of Claim 39 wherein Z is represented by a structural formula selected from:
wherein:
X1 is -S-, -CH2- or -CH2S-;
W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl;
Ring A is substituted with R8 and R9;
R8 and R9 are each, independently, -H, a halogen, alkoxy or alkyl, or R8 and R9, taken together with Ring A, form a naphthyl group;
n is an integer from 2-5;
M is >N(alkanoyl), >N(aroyl), >N (aralkoyl), >N(alkyl), >N (aralkyl), >N(cycloalkyl), >C(OH)(aryl) or >CH(heteroaryl).
wherein:
X1 is -S-, -CH2- or -CH2S-;
W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl;
Ring A is substituted with R8 and R9;
R8 and R9 are each, independently, -H, a halogen, alkoxy or alkyl, or R8 and R9, taken together with Ring A, form a naphthyl group;
n is an integer from 2-5;
M is >N(alkanoyl), >N(aroyl), >N (aralkoyl), >N(alkyl), >N (aralkyl), >N(cycloalkyl), >C(OH)(aryl) or >CH(heteroaryl).
42. The use of Claim 38 wherein the compound is represented by a structural formula selected from:
43. The use of Claim 38 wherein Z is represented by a structural formula selected from:
wherein Rings A, B and C are each, independently, substituted or unsubstituted.
wherein Rings A, B and C are each, independently, substituted or unsubstituted.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/010,321 | 1998-01-21 | ||
US09/010,321 US6323206B1 (en) | 1996-07-12 | 1998-01-21 | Chemokine receptor antagonists and methods of use therefor |
PCT/US1999/001265 WO1999037617A1 (en) | 1998-01-21 | 1999-01-21 | Chemokine receptor antagonists and methods of use therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2318100A1 true CA2318100A1 (en) | 1999-07-29 |
Family
ID=21745208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002318100A Abandoned CA2318100A1 (en) | 1998-01-21 | 1999-01-21 | Chemokine receptor antagonists and methods of use therefor |
Country Status (6)
Country | Link |
---|---|
US (2) | US6323206B1 (en) |
EP (1) | EP1049675A1 (en) |
JP (1) | JP2002501050A (en) |
AU (1) | AU2331899A (en) |
CA (1) | CA2318100A1 (en) |
WO (1) | WO1999037617A1 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
US6339087B1 (en) | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
US6613905B1 (en) | 1998-01-21 | 2003-09-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
EP1047675A1 (en) | 1998-01-21 | 2000-11-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6509346B2 (en) | 1998-01-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
DE69928226T8 (en) | 1998-01-21 | 2006-10-19 | Millennium Pharmaceuticals, Inc., Cambridge | CHEMOKIN RECEPTOR ANTAGONISTS AND USE |
US7271176B2 (en) * | 1998-09-04 | 2007-09-18 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use thereof |
TR200101155T2 (en) * | 1998-11-17 | 2001-09-21 | F. Hoffmann-La Roche Ag | 4-Aroil Piperidine CCR-3 Receptor Antagonists III |
EP1131290B1 (en) * | 1998-11-20 | 2008-02-20 | F. Hoffmann-La Roche Ag | Piperidine ccr-3 receptor antagonists |
US7217714B1 (en) * | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
PE20001420A1 (en) * | 1998-12-23 | 2000-12-18 | Pfizer | CCR5 MODULATORS |
EP1013276A1 (en) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
JP2002535358A (en) * | 1999-01-29 | 2002-10-22 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Methods for preventing graft rejection and ischemia-reperfusion injury |
EP1204640A2 (en) * | 1999-07-28 | 2002-05-15 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
ES2311126T3 (en) * | 2000-05-26 | 2009-02-01 | Pfizer Inc. | DERIVATIVES OF TRIAZOLIL TROPANO AS MODULATORS OF CCR5. |
US6667314B2 (en) | 2000-05-26 | 2003-12-23 | Pfizer, Inc. | Tropane derivatives useful in therapy |
GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
US6740636B2 (en) * | 2000-07-31 | 2004-05-25 | Schering Aktiengesellschaft | Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection |
GB0021670D0 (en) | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
GB0117899D0 (en) | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
US7541365B2 (en) * | 2001-11-21 | 2009-06-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
TWI291467B (en) * | 2002-11-13 | 2007-12-21 | Millennium Pharm Inc | CCR1 antagonists and methods of use therefor |
US7378426B2 (en) * | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7417040B2 (en) * | 2004-03-01 | 2008-08-26 | Bristol-Myers Squibb Company | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
CN105646459A (en) * | 2014-11-13 | 2016-06-08 | 上海和辉光电有限公司 | Compound and preparation method and application thereof |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE80449C (en) | ||||
FR145F (en) | 1964-06-01 | |||
US3625974A (en) | 1967-04-28 | 1971-12-07 | Fujisawa Pharmaceutical Co | Dibenzothiazepine derivatives |
NL6905642A (en) | 1968-04-12 | 1969-10-14 | ||
US3907812A (en) | 1969-07-16 | 1975-09-23 | Sumitomo Chemical Co | Butyrophenone derivatives |
US3936468A (en) | 1969-10-27 | 1976-02-03 | Sumitomo Chemical Company, Ltd. | Phenylbutanol derivatives |
DE2163657A1 (en) | 1970-12-22 | 1972-07-13 | Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan) | N-substituted piperidine compounds |
GB1330966A (en) | 1970-12-22 | 1973-09-19 | Yoshitomi Pharmaceutical | N-substituted piperidine compounds methods for their production and pharmaceutical compositions containing them |
US3922266A (en) | 1972-06-28 | 1975-11-25 | Sumitomo Chemical Co | Aryl ketones and production thereof |
US4086234A (en) | 1975-11-07 | 1978-04-25 | G. D. Searle & Co. | Process for the preparation of tertiary amines |
US4250176A (en) | 1976-12-21 | 1981-02-10 | Janssen Pharmaceutica N.V. | Piperazine derivatives |
US4125612A (en) | 1977-06-20 | 1978-11-14 | Schering Corporation | N-1-(p-Biphenylalkyl)piperazines and their use as anti-inflammatory agents |
US4335122A (en) | 1981-03-18 | 1982-06-15 | Hoechst-Roussel Pharmaceuticals Inc. | Dihydro-dibenzoxepines-thiepines and -morphanthridones, compositions and use |
CA1237428A (en) | 1983-06-24 | 1988-05-31 | Hiroshi Tanaka | ¬1| benzepino¬3,4-b|pyridine derivative |
SE8500273D0 (en) | 1985-01-22 | 1985-01-22 | Leo Ab | NEW TRICYCLIC ASSOCIATIONS, COMPOSITIONS CONTAINING SUCH ASSOCIATIONS, MANUFACTURING PROCEDURES AND METHODS OF TREATMENT |
JPS6229558A (en) | 1985-07-30 | 1987-02-07 | Yoshitomi Pharmaceut Ind Ltd | Benzophenone derivative |
JPS6310784A (en) | 1986-03-03 | 1988-01-18 | Kyowa Hakko Kogyo Co Ltd | Dibenz(b,e)oxepin derivative, antiallergic agent and anti-inflammatory agent |
WO1988000049A1 (en) | 1986-06-26 | 1988-01-14 | Kyowa Hakko Kogyo Co., Ltd. | Antiarrhythmic agent |
US5089496A (en) | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
US4882351A (en) | 1987-10-14 | 1989-11-21 | Roussel Uclaf | Tricyclic compounds |
AU612437B2 (en) | 1987-12-14 | 1991-07-11 | Kyowa Hakko Kogyo Co. Ltd. | Tricyclic compounds |
MY106280A (en) | 1988-04-28 | 1995-04-29 | Schering Corp | Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use. |
US5242931A (en) | 1988-06-09 | 1993-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as TXA2 antagonists |
CA1338625C (en) | 1988-06-09 | 1996-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
WO1990013539A1 (en) | 1989-04-28 | 1990-11-15 | Meiji Seika Kaisha, Ltd. | New n-substituted piperazine derivatives and drug for improving functional disorder of brain |
JPH0694464B2 (en) | 1991-01-23 | 1994-11-24 | 協和醗酵工業株式会社 | Tricyclic compound and its intermediate |
WO1992020681A1 (en) | 1991-05-23 | 1992-11-26 | Schering Corporation | Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use |
CA2114009A1 (en) | 1991-07-23 | 1993-02-04 | Jesse K. Wong | Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use |
US5378701A (en) | 1991-12-27 | 1995-01-03 | Kyowa Hakko Kogyo | Tricyclic compounds |
US5679703A (en) | 1992-09-16 | 1997-10-21 | Kyowa Hakko Kogyo, Co., Ltd. | Tricyclic compounds having ACAT inhibiting activity |
US5538986A (en) * | 1993-12-06 | 1996-07-23 | Schering Corporation | Tricyclic derivatives, compositions and methods of use |
MY113463A (en) | 1994-01-04 | 2002-03-30 | Novo Nordisk As | Novel heterocyclic compounds |
WO1996031469A1 (en) | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | N-substituted azaheterocyclic carboxylic acids and esters thereof |
UA54385C2 (en) | 1995-04-07 | 2003-03-17 | Ново Нордіск А/С | N-substituted azaheterocyclic carboxylic acids and etHers thereof, a method for THEIR PREPARATION, a pharmaceutical composition and a method for treatment |
US5712280A (en) | 1995-04-07 | 1998-01-27 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5801175A (en) | 1995-04-07 | 1998-09-01 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
AU5271096A (en) | 1995-04-07 | 1996-10-23 | Novo Nordisk A/S | Novel heterocyclic compounds |
JPH0940662A (en) | 1995-05-24 | 1997-02-10 | Kyowa Hakko Kogyo Co Ltd | Tricyclic compound |
DE69621469T2 (en) | 1995-09-13 | 2002-12-12 | Kyowa Hakko Kogyo Co., Ltd. | Phenylpiperidine compounds |
WO1997024325A1 (en) | 1995-12-28 | 1997-07-10 | Takeda Chemical Industries, Ltd. | DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS |
EP0914319B1 (en) | 1996-05-20 | 2001-11-21 | Teijin Limited | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists |
US6281212B1 (en) | 1996-07-12 | 2001-08-28 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
AU3633997A (en) | 1996-07-29 | 1998-02-20 | Banyu Pharmaceutical Co., Ltd. | Chemokine receptor antagonists |
WO1998027815A1 (en) | 1996-12-20 | 1998-07-02 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
WO1998043638A1 (en) | 1997-03-27 | 1998-10-08 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for autoimmune diseases |
DE69835877T2 (en) | 1997-04-15 | 2007-05-16 | Kyowa Hakko Kogyo Co., Ltd. | TRICYCLIC CONNECTIONS |
US5877177A (en) | 1997-06-17 | 1999-03-02 | Schering Corporation | Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US6040318A (en) | 1997-06-25 | 2000-03-21 | Novo Nordisk A/S | Tricycle substituted with azaheterocyclic carboxylic acids |
US6048856A (en) | 1997-12-17 | 2000-04-11 | Novo Nordisk A/S | Heterocyclic compounds |
-
1998
- 1998-01-21 US US09/010,321 patent/US6323206B1/en not_active Expired - Lifetime
-
1999
- 1999-01-21 CA CA002318100A patent/CA2318100A1/en not_active Abandoned
- 1999-01-21 EP EP99903254A patent/EP1049675A1/en not_active Withdrawn
- 1999-01-21 AU AU23318/99A patent/AU2331899A/en not_active Abandoned
- 1999-01-21 WO PCT/US1999/001265 patent/WO1999037617A1/en not_active Application Discontinuation
- 1999-01-21 JP JP2000528541A patent/JP2002501050A/en active Pending
-
2001
- 2001-10-02 US US09/969,566 patent/US20020151553A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6323206B1 (en) | 2001-11-27 |
EP1049675A1 (en) | 2000-11-08 |
US20020151553A1 (en) | 2002-10-17 |
AU2331899A (en) | 1999-08-09 |
JP2002501050A (en) | 2002-01-15 |
WO1999037617A1 (en) | 1999-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2318100A1 (en) | Chemokine receptor antagonists and methods of use therefor | |
US6433165B1 (en) | Chemokine receptor antagonists and methods of use therefor | |
AU729415B2 (en) | Chemokine receptor antagonists and methods of use therefor | |
EP1615647B1 (en) | Pharmaceutical use of fused 1,2,4-triazoles | |
AU2006310518A1 (en) | Pharmaceutical use of substituted amides | |
JP2009539937A (en) | Pharmaceutical use of substituted piperidine carboxamides | |
JP2009542759A (en) | 4-piperidylbenzamide as 11-β-hydroxysteroid dehydrogenase type 1 inhibitor | |
JP2004506593A (en) | Cyclic amine derivatives and their uses | |
WO2000014086A1 (en) | Chemokine receptor antagonists and methods of use therefor | |
EP1109815A1 (en) | Chemokine receptor antagonists and methods of use therefor | |
JP4429738B2 (en) | 4,4-disubstituted piperidine derivatives having CCR3 antagonistic activity | |
WO2001009137A1 (en) | Chemokine receptor antagonists and methods of use therefor | |
EP2286811B1 (en) | Chemokine receptor antagonists and methods of use thereof | |
EP1202985A2 (en) | Chemokine receptor antagonists | |
MXPA00007142A (en) | Chemokine receptor antagonists and methods of use therefor | |
EP1204640A2 (en) | Chemokine receptor antagonists and methods of use therefor | |
MXPA00007141A (en) | Chemokine receptor antagonists and methods of use therefor | |
AU4015901A (en) | Chemokine receptor antagonists and methods of use therefor | |
MXPA01002346A (en) | Chemokine receptor antagonists and methods of use therefor | |
MXPA01002345A (en) | Chemokine receptor antagonists and methods of use therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |